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Drug research is a unique multi-disciplinary process leading to the development of 
novel therapeutic agents for disease states that have unmet needs. Traditional health 
care systems, using medicinal plants, can be recognized and used as a starting point 
for the development of novelty in drugs (NCE). The plants are rich reservoir of 
potential leads for drug discovery against various disorders. The desire of searching 
new potential candidates for various disease have opened new venue in the field of 
drug discovery. 
One such target could be phytohormones – a field which is relatively untouched so 
far. In plants, each developmental process integrates a network of signaling events 
that are regulated by different phytohormones, and interactions among hormonal 
pathways are essential to modulate their effect. As human hormones significantly 
affect the activity of every cell in the body such as influence on mental activity, 
physical agility, and body build and stature; plant hormones also do play vital 
functions in wide varieties of plant kingdom. The hormone concept as developed for 
animals cannot easily be translated to plants. Still, plants have regulated growth, 
determined steps of differentiation, different metabolic rates in cells, and 
communication between cells (Cerana, 2006; Farnsworth, 1976). Phytohormones 
regulate most of the life cycle events in plants at genetic level including germination, 
cell division and extension, flowering, fruit ripening, seed dormancy and death. 
Plant biologists believe that hormones exert their effects via specific receptor sites in 
target cells, similar to the mechanisms found in animals (Farnsworth, 1976). The 
number of different plant hormones is rather small when compared to animals. Many 
animal hormones, especially the macromolecular ones have a very limited action 
spectrum that has its root in the selectivity and the cell-specific or tissue-specific 
distribution of the respective receptors. In contrast the receptors for plant hormones 
have wide-spread distribution.  
Many of plant hormones have been tested for their usefulness in disease status. Plant 
stress hormones activate cellular responses, including cell death, to diverse stress 
situations in plants. Researchers have found that some plant stress hormones share the 
ability to adversely affect human cancer cells. For example, sodium salicylate has 
been found to suppress proliferation of lymphoblastic leukemia, prostate, breast, and 
melanoma human cancer cells (Flescher and Eliezer, 2005). Jasmonates induced death 
 Introduction 
[10] Devang B. Sheth 
in leukemic cells isolated from the blood of chronic lymphocytic leukemia (CLL) 
patients and increased significantly the survival of lymphoma-bearing mice (Fingrut 
and Flescher, 2002; Flescher and Eliezer, 2005). Methyl jasmonate has been found to 
induce cell death in a number of cancer cell lines. Steroidal plant hormone, 24-
epibrassinolide can be used for the treatment of infections caused by virus responsible 
for human immune deficiency (HIV). Plant hormones have beneficial effects on the 
human immune system, particularly the gibberellins and abscisic acid. Natural 
hormone replacement therapy (NHRT) is used to treat hormone imbalances and 
deficiencies in some cases. 
Recent studies on some phytohormones, both in-vivo and in-vitro, have opened a new 
avenue to discover new chemical entities in the field of phyto-pharmacology.  
One such promising molecule is abscisic acid. Since its discovery in 1965, abscisic 
acid (ABA) has received considerable attention as an important phytohormone, and 
more recently, as a candidate medicinal in humans. In plants it has been shown to 
regulate important physiological processes such as response to drought stress, and 
dormancy. The discovery of ABA synthesis in animal cells has generated interest in 
the possible parallels between its role in plant and animal systems. ABA recognition 
in plants has been shown to occur at both the intra- and extracellularly but little is 
known about the perception of ABA by animal cells. A few ABA molecular targets 
have been identified in vitro (e.g., calcium signalling, G protein-coupled receptors) in 
both plant and animal systems. 
The isoprenoid phytohormone abscisic acid (ABA), commonly known as one of the 
five major classes of plant hormones, plays important roles during many phases of the 
plant life cycle including seed development and dormancy, in plant responses to 
various environmental stresses and host response. ABA is unique from other 
phytohormones such as auxins, giberellins, and cytokinins in that it is a single 
compound, rather than a class of phytohormones, and is now known to be ubiquitous 
in Viridiplantae (green plants). ABA activity has also been reported in fungi 
(Tsavkelova et al., 2006), marine sponges (Zocchi et al., 2001; Zocchi et al., 2003) 
and most recently in human cells (Bruzzone et al., 2007; Magnone et al., 2009). ABA 
research has taken a new turn outside the world of plant physiology with the 
publication of a series of papers showing biological activity in mammalian cells and 
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pre-clinical studies suggesting a possible role for ABA as potential therapeutic agent. 
Hence, in the present project we resolved to explore pharmacological profile of 
abscisic acid which, on further investigations, could lead to discovery of its 
therapeutic potential.   
Over the past 30 years, as obesity rates have surged towards epidemic proportions, 
health practitioners have reported an attendant rise in the number of patients 
diagnosed with insulin resistance (Finkelstein et al., 2003), a condition characterized 
by the diminished ability of muscle or other peripheral tissues to uptake glucose from 
the bloodstream. According to the most recent World Health Organization estimates, 
1.6 billion adults are overweight and 300 million are obese. One of the consequences 
of insulin resistance is chronic hyperglycemia, which induces the micro and 
macrovascular disorders associated with Type 2 Diabetes (T2D) (Vasudevan, 2006). 
In addition to T2D, however, researchers are finding that the costs of insulin 
resistance extend to many chronic diseases, including coronary vascular disease 
(CVD), atherosclerosis, and hypertension (Center for Disease Control and Prevention, 
2005). 
Because even moderate insulin resistance puts one at an elevated risk for developing 
CVD and other insulin resistance-related chronic diseases, a number of questions have 
arisen concerning when patients should begin taking an anti-diabetic medication and 
also what type of medication they should be prescribed. The more traditional anti-
diabetic treatments include the sulfonylureas and α-glucosidase inhibitors, which 
reduce the consequences of chronic hyperglycemia by increasing pancreatic insulin 
secretion and inhibiting intestinal glucose absorption, respectively (Center for Disease 
Control and Prevention, 2005). These drugs, however, are designed to manage 
hyperglycemia rather than treat it, and they do not have any significant effect on the 
progression of insulin resistance. Because of this, they are often used in conjunction 
with the newer class of anti-diabetic treatments known as the “insulin sensitizers.” 
As their name implies, “insulin sensitizers” increase the sensitivity of peripheral 
tissues to the actions of endogenous insulin, thereby directly counteracting the effect 
of obesity. The two main classes of insulin-sensitizing drugs include the biguanides 
(i.e. metformin) and thiazolidinediones (TZDs, i.e. rosiglitazone and pioglitazone). 
While both are classified as “insulin sensitizers,” biguanides and TZDs act through 
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distinct molecular mechanisms. Biguanides lower hepatic glucose production and 
increase intramyocellular fatty acid oxidation by increasing the activity of the signal 
transduction protein AMP kinase (AMPK) (Zhou et al., 2001). Conversely, TZDs 
serve as synthetic ligands for a key metabolic regulator and transcription factor known 
as peroxisome proliferator-activated receptor γ (PPAR γ) (Lehmann et al., 1995). 
PPAR γ is a member of the nuclear receptor superfamily, which consists of 48 ligand-
induced transcription factors that respond to nutrients, xenobiotics, and various 
hormones and endogenously produced compounds, and is found in high 
concentrations in white adipose tissue (WAT), immune cells, and the colonic 
epithelium (Braissant et al., 1996; Desvergne and Wahli, 1996). PPARs, which in 
addition to PPAR γ also include PPARs α and δ, are endogenously activated by fatty 
acids and products of lipid metabolism (Desvergne and Wahli, 1996). 
One notable difference between the biguanides and TZDs is that the latter, perhaps 
due to activating a central metabolic regulator, have the added benefits of being anti-
hypertensive and anti-atherogenic (Wang et al., 2005; Dobrian et al., 2004; Scheen 
and Lefebvre, 2005). Comparisons between biguanides and TZDs have indicated that 
TZDs are more effective in improving glycemic control and in enhancing whole body 
insulin sensitivity (Seufert et al., 2004; Knowler et al., 2005). Therefore, with regard 
to the insulin sensitizing medications, PPAR γ agonists in particular appear to 
represent a more promising avenue for future drug design and disease 
treatment/prevention. 
While TZDs have shown effectiveness in improving insulin sensitivity in patients 
with both T2D and prediabetes (Dumasia et al.,  2005), these compounds, as are the 
case with many pharmaceutical agents, are associated with a number of unwanted side 
effects which limit their desirability and availability to millions of potential users 
(Nesto et al., 2003). For instance, in some recent clinical trials pioglitazone has been 
shown to increase the incidences of both edema and congestive heart failure 
(Dormandy et al., 2005; Scheen and Lefebvre, 2005). TZDs are also associated with 
weight gain and, in the past, hepatotoxicity (Nesto et al., 2003). Recently, a study in 
the New England Journal of Medicine showed that use of rosiglitazone was associated 
with a 43% increase in myocardial infarction and 64% increase in risk of 
cardiovascular mortality (Nissen SE and Wolski, 2007). With regard to TZDs, there 
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are still many questions concerning how PPAR γ ligands improve systemic insulin 
sensitivity. 
Abscisic acid is structurally similar to thiazolidinediones. Moreover, PPAR γ -
responsive genes were found to be induced or activated by abscisic acid in 3T3-L1 
preadipocytes in vitro (Guri et al., 2008; Lehmann et al., 1995). It is also found that 
ABA could be used as a nutritional supplement to combat type II diabetes and 
obesity-related inflammation (Guri et al., 2007). In the light of these facts, in present 
project we resolved to investigate pharmacological effects of abscisic acid on insulin 
resistance. 
Cancer is a class of diseases in which, a group of cells display the traits of 
uncontrolled growth (growth and division beyond the normal limits), invasion 
(intrusion on and destruction of adjacent tissues), and sometimes metastasis (spread to 
other locations in the body via lymph or blood). (Fodde R and Smits R, 2002; Merlo 
et al., 2006). Today it is believed that cancer is a leading cause of death where it 
accounts for 7.6 million deaths which are about 13% of all deaths in 2008 (WHO, 
2011). The main types of cancer leading to overall cancer mortality each year are lung 
(1.3 million deaths/year), stomach (803000 deaths), colorectal (639000 deaths), liver 
(610000 deaths) and breast (519000 deaths) (Garcia et al., 2007). More than 70% of 
all cancer deaths occurred in low- and middle-income countries (Boyle and Levin, 
2008; WHO, 2011). Deaths from cancer worldwide are projected to continue rising, 
with an estimated 12 million deaths in 2030 (WHO, 2011). Breast cancer, for 
instance, is the most common cancer disease in woman globally. The American 
Cancer Society estimated that in year 2008, about 182,460 women in the USA will be 
diagnosed with it and 40,480 women will die of breast cancer (Kelly, 2008). Breast 
cancer is currently the top cancer in women worldwide, both in the developed and the 
developing world (WHO, 2011). 
Most of anti-cancer drugs lead to serious adverse effects like immune suppression, 
hair loss, nausea, vomiting, etc. They are also associated with occurrence of 
irreversible degenerative cardiomyopathy, hepatotoxicity, nephrotoxicity, ototoxicity, 
and encephalopathy which limits their clinical usefulness (Rang et al., 2005). There 
are many kinds of drugs that have been discovered and used as an alternative 
treatment to stop the progressive growing and spreading of the breast cancer such as 
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selective estrogen receptor modulators (e.g. Tamoxifen) and aromatase inhibitors (e.g. 
anastrozole, exemestane) (Newman and Cragg, 2006). Possible side effects of SERMs 
include fatigue, hot flashes, increased chances of endometrial cancer and vaginal 
dryness. Side effects of aromatase inhibitors include joint and muscle pain, as well as 
an increased risk of bone thinning (osteoporosis) (Rang et al., 2005). Clearly, these 
serious side effects limit the overall clinical utility of these compounds. Even targeted 
drug treatments, which attack specific abnormalities within cancer cells, like 
trastuzumab and bevacizumab also are associated with serious adverse drug effects 
like cardiotoxicity, high blood pressure, sore mouth, skin rashes etc. Thus, search for 
novel and safe drug in breast cancer is desirable. The discovery of a new alternative 
medicine which is more to natural basis is highly welcome. 
Recently, there is increasing interest in the search for plant based hormones for the 
development of new pharmaceuticals, along with the increase of deadly illness such 
as cancer (Newman et al., 2003). Many phytohormones such as jasmonates and 
salicylates have been shown to suppress growth of various types of cancer cells 
(Flescher and Eliezer, 2005).  
Limited information is available in the peer-reviewed literature regarding the possible 
role of ABA in the prevention and treatment of cancer. However, a patent was issued 
to Livingston-Wheeler in 1976 for its use as an anti-cancer compound (Livingston, 
1976). The patent describes the use of a solid myeloid leukemia C1498 
transplantation model in C57BL/6 mice to investigate the anti-cancer efficacy of 
ABA. The inventor reported increased survival rates at 14 days post-transplantation in 
mice treated with ABA in comparison to control mice. The inventor also proposed 
that ABA “neutralized” the human chorionic gonadotropin (hCG) that reportedly 
coated cancer cells, thereby facilitating anti-cancer immune responses ABA may 
represent a potential cancer treatment due to its ability to modulate calcium signalling 
(Livingston, 1976). More specifically, modulates pathways in plants and animals 
involving cADPR which control the increase in [Ca+2]int (Wu et al., 1997). In plants, 
ABA depolarizes plasma membranes, which activates potassium ion channels and 
thereby extrudes K+ outside the cells (Schroeder et al., 1987). Ion channel 
depolarization is dependent on calcium, which is an ABA second messenger 
(Schroeder et al., 2001). The increase in calcium concentrations also leads to 
increased nitric oxide (NO) production (Bodrato et al., 2009). As calcium signaling is 
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a key regulator of apoptosis, changes in calcium distribution in the cell activate 
cellular cascades which lead to cell death (Hajnoczky et al., 2003). 
Mechanistically, some of the pathways activated by ABA and those modulated by 
chemotherapeutic agents used for treating cancer are strikingly similar. For instance, 
several chemotherapeutic agents modulate pathways leading to increased intracellular 
calcium concentrations. Medications such as staurosporine, doxorubicin, tamoxifen, 
and etoposide act as anti-cancer agents which lead to the death of cancer cells by 
increasing [Ca+2]int resulting in oxidative stress followed by apoptosis (Kruman et al., 
1998; Panaretakis et al., 2005; Parihar et al., 2008). 
Moreover, epidemiologic studies demonstrated that the consumption of diet rich in 
abscisic acid is associated with a decreased risk of cancer (Riboli and Norat, 2003; 
Wigmore, 1985). Dr. Ann Wigmore mentioned that wheatgrass contains a variety of 
elements that is believed to be anticancer and abscisic acid is one of them. She 
reported that wheatgrass and controlled diet cured breast cancer of few patients. Even 
in experimental animal showed that even a tiny amount of abscisic acid has 
tremendous effect on cancer (Wigmore, 1985). Tan et al. (2006) reported in a China 
patent that ABA effectively inhibits the proliferation of tumour cells; stagnates the 
cells in S phase, stops cell division, and induces differentiation of tumour cells or 
reverts cancerous cells to normal cells. ABA was reported to inhibit proliferation and 
induced differentiation in human SMMC- 7221 cells (Ma et al., 2006) and in nude 
mice transplanted with human hepatocarcinoma (Lu et al., 2007). Thus, exploring the 
role of ABA in cancer prevention and treatment in the context of well controlled, 
mechanistically oriented projects may result in the development of novel ABA-based 
chemotherapeutic approaches against cancer. Additionally, abscisic acid is a close 
relative of Vitamin A. All these findings and observations suggest strong anti-cancer 
potential of abscisic acid. 
Low cytotoxicity to healthy cells and high cytotoxicity to cancerous cells is the 
ultimate goal of many chemotherapy drugs. In-vitro cell based cytotoxicity assay is an 
easy and cost effective tool for early stage of drug discovery. Most of the commonly 
used cytotoxic anticancer drugs were discovered through random high-throughput 
screening of synthetic compounds and natural products in cell based cytotoxicity 
assays. In vitro cytotoxicity assays has been used to rapidly evaluate the potential 
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toxicity of large numbers of compounds, to limit animal experimentation whenever 
possible, and to carry out tests with small quantities of compound. Hence, in the 
present project, we decided to screen abscisic acid for potential in-vitro anticancer 
activity in breast cancer cell-lines. 
Calcium is the most important regulator of cell function. Many physiological 
mechanisms and drugs operate, directly or indirectly, by influencing the free intra 
cellular concentration of calcium. Different types of Ca+2 channels are involved in 
important physiological functions such as contraction of muscles, activation of 
various enzymes, release of neurotransmitters and hormones, etc. Intracellular 
calcium is usually bound to a protein called calmodulin. The calcium-calmodulin 
complex acts together with a further component (RE, response element, also a 
protein) as a protein kinase catalyzing the phosphorylation of numerous proteins that 
themselves control independent but partially parallel developmental processes, 
differentiation, and movements within the cell (Rang et al., 2005). Abnormal Ca+2 
signalling is involved in many pathophysiological conditions, such as, cardiac 
dysrhythmias, hypertension, epileptogensis, ischaemic cell death, and endocrine 
disorders. Many clinically important drugs like anti-hypertensive agents (e.g. 
nifedine, verapamil, diltiazem); anti-epileptic drugs (e.g. ethosuximide, sodium 
valproate, gabapentin, pregabalin); antidysrhythmic agents (e.g. class-IV 
antidysrhythmic agents), spasmolytic agents, etc. act directly or indirectly by blocking 
calcium release (Rang et al., 2005). 
Over the past few years, evidence from a variety of sources has suggested that 
calcium ions are involved in the molecular events underlying the action of growth 
substance in plants (De Silva et al., 1985). Ca+2 is a second messenger and 
intracellular regulator which regulates of growth and development in plants (Hepler, 
2005). 
Recent studies of the control of stomatal aperture by abscisic acid have suggested that 
its cellular action depends on the availability of calcium ions, which appear to 
function as secondary messengers. In plants, it has been demonstrated that ABA 
stimulates the release of intracellular calcium in conjunction with the up-regulation of 
cyclic ADP-ribose (Wu et al., 1997). In plants, ABA depolarizes plasma membranes, 
which activates potassium ion channels and thereby extrudes K+ outside the cells 
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(Schroeder et al., 1987). Ion channel depolarization is dependent on calcium, which is 
an ABA second messenger (Schroeder et al., 2001). The increase in calcium 
concentrations also leads to increased nitric oxide (NO) production (Bodrato et al., 
2009). Huddart et al. (1986) found that ABA may serve as a universal Ca+2 agonist 
across taxonomic kingdoms based on experiments with various smooth muscle 
preparations and a cyanobacterium. 
In contrast, Lynch et al (1991) reported that abscisic acid (ABA) analogue SD217595 
inhibits K+-induced phasic and tonic contractions of rat bladder detrusor smooth 
muscle strips. This dual inhibition was hypothesized due to blockade of two subtypes 
of voltage-operated calcium channels with T- and L-type characteristics. This was 
further supported by finding that ABA is without significant Ca+2 modulatory activity 
in rat prostatic and epididymal vas deferens smooth muscle preparation but the ABA 
analogue SD217595 possesses strong Ca+2 entry blocking ability (Masters et al., 
1994). Thus, role of abscisic acid in relevance to its Ca+2 channel modulatory action is 
controversial. Hence, in the present study, we attempted to assess effects of Ca+2 
channel modulatory action of abscisic acid, using isolated rat ileum and in-vivo 
effect on various cardiac parameters in rat. 
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3.1 Plant hormones 
Hormones in plants are called phytohormones. They are small molecules distributed 
within tissues from cell to cell, as in the case of auxins, via vascular bundles (as in the 
case of cytokinin), or via the intercellular space (ethylene). A number of results 
indicate that phytohormones enter cells and regulate intracellular processes, though 
hardly anything about their intracellular distribution or about their transport from one 
compartment into another is known. It remains open, too, whether they are stored in 
one or the other compartment, and whether they become biologically active by being 
set free from such compartments. 
They regulate most of the life cycle events in plants, such as germination, cell division 
and extension, flowering, fruit ripening, seed dormancy and death. Five plant 
hormones have long been identified: auxin, cytokinin, gibberellin, abscisic acid, and 
ethylene. Recent discoveries of other plant hormones include brassinosteroids, 
salicylates, and jasmonates (Kletter et al., 1997). 
Auxins are primarily responsible for protein synthesis and promote the growth of the 
plant's length. The most common auxin, indoleacetic acid (IAA), is usually formed 
near the growing top shoots and flows downward, causing newly formed leaves to 
grow longer. Auxins stimulate growth toward light and root growth (Kokate et al., 
2007). 
Gibberellins, which form in the seeds, young leaves, and roots, are also responsible 
for protein synthesis, especially in the main stem of the plant. Unlike auxins, 
gibberellins move upward from the roots (Kokate et al., 2007). Cytokinins form in the 
roots and move up to the leaves and fruit to maintain growth, cell differentiation, and 
cell division. Among the growth inhibitors are abscisic acid, which promotes 
abscission, or leaf fall; dormancy in buds; and the formation of bulbs or tubers, 
possibly by preventing the synthesis of protein. 
Ethylene, another inhibitor, also causes abscission, perhaps by its destructive effect on 
auxins, and it also stimulates the ripening of fruit. 
Brassinosteroids act with auxins to encourage leaf elongation and inhibit root growth. 
Brassinosteroids also protect plants from some insects because they work against 
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some of the hormones that regulate insect molting. Salicylates stimulate flowering and 
cause disease resistance in some plants. Jasmonates regulate growth, germination, and 
flower bud formation. They also stimulate the formation of proteins that protect the 
plant against environmental stresses, such as temperature changes or droughts. 
3.2 Abscisic acid 
3.2.1 Introduction 
The isoprenoid phytohormone abscisic acid (ABA), commonly known as one of the 
five major classes of plant hormones, plays important roles during many phases of the 
plant life cycle including seed development and dormancy, in plant responses to 
various environmental stresses and host response. ABA is unique from other 
phytohormones such as auxins, giberellins, and cytokinins in that it is a single 
compound, rather than a class of phytohormones, and is now known to be ubiquitous 
in Viridiplantae (green plants) (Bassaganya-Riera et al., 2010). It was called "abscisin 
II" originally because it was thought to play a major role in abscission of fruits. At 
about the same time another group was calling it "dormin" because they thought it had 
a major role in bud dormancy.  Eventually, the roles of ABA in bud dormancy and 
abscission are now found to be minor. Though ABA generally is thought to play 
mostly inhibitory roles, it has many promoting functions as well (Arteca, 1996; 
Mauseth, 1991; Raven, 1992; Salisbury and Ross, 1992). Abscisic acid has previously 
been extracted from leaves of Lupin (Lupinus cosentinii), Apricot (Prunus 
armeniaca), Avocado (Persea Americana), Sunflower (Helianthus annuus), 
Grapevine (Vitis vinifera), Tomato (Lycopersicon esculentum), Spinach (Spinada 
oleracea), Orange (Citrus sinensis) and Mango (Mangifera indica) (Loveys BR and 
van Dijk HM, 1988). ABA and its metabolites have also been isolated from Brassica 
napus and Brassica rapa seed (Zhou et al., 2004). 
3.2.2 History of abscisic acid 
In 1963, abscisic acid was first identified and characterized by Frederick Addicott and 
his associates. It was first isolated in studies relating plant compounds with bud 
dormancy and fruit abscission (cotton), and hence was initially known as dormin or 
abscissin. Ironically, the roles of ABA in bud dormancy and abscission are now 
considered to be minor. Two compounds were isolated and called abscisin I and 
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abscisin II. Abscisin II is presently called abscisic acid (ABA) (Addicot, 1963). Two 
other groups at about the same time discovered the same compound. One group 
headed by Philip Wareing was studying bud dormancy in woody plants. The other 
group led by Van Steveninck was studying abscission of flowers and fruits from 
lupine. Plant physiologists agreed to call the compound abscisic acid (Salisbury and 
Ross, 1992). 
3.2.3 Biosynthesis and Metabolism 
ABA is a naturally occurring compound in plants. It is a sesquiterpenoid (15-carbon) 
which is partially produced via the mevalonic pathway in chloroplasts and other 
plastids. Because it is sythesized partially in the chloroplasts, it makes sense that 
biosynthesis primarily occurs in the leaves. The production of ABA is accentuated by 
stresses such as water loss and freezing temperatures. It is believed that biosynthesis 
occurs indirectly through the production of carotenoids. Carotenoids are pigments 
produced by the chloroplast which have 40 carbons. Breakdown of these carotenoids 
occurs by the following mechanism:  
Violaxanthin is a carotenoid which has forty carbons.  It is isomerized and then split 
via an isomerase reaction followed by an oxidation reaction. One molecule of 
xanthonin is produced from one molecule of violaxanthonin and it is uncertain what 
happens to the remaining biproduct. The one molecule of xanthonin produced is 
unstable and spontaneously changed to ABA aldehyde. Further oxidation results in 
ABA.  
Activation of the molecule can occur by two methods. In the first method, an ABA-
glucose ester can form by attachment of glucose to ABA. In the second method, 
oxidation of ABA can occur to form phaseic acid and dihyhdrophaseic acid.  
The transport of ABA can occur in both xylem and phloem tissues. It can also be 
translocated through paranchyma cells. The movement of abscisic acid in plants does 
not exhibit polarity like auxins. ABA is capable of moving both up and down the stem 
(Walton and Li, 1995; Salisbury and Ross, 1992). 
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3.2.4 Functions of Abscisic Acid in plants 
The following are some of the physiological responses known to be associated with 
abscisic acid (Davies, 1995; Mauseth, 1991; Raven, 1992; Salisbury and Ross, 1992). 
• Stimulates stomatal closure, in order to reduce transpiration and prevent water 
loss. The action of ABA can specifically target guard cells for induction of 
stomatal closure but may also produce a systemic response during periods of 
drought stress. The regulation of stomatal opening and closure is critical to a 
plants ability to control water loss. Thus, ABA plays a major role as an 
endogenous messenger in the regulation of plant’s water status (McAinsh, 
1990). 
• Inhibits fruit-ripening  
• Encourages seed dormancy by inhibiting cell growth – inhibits seed 
germination  
• Inhibits the uptake of Kinetin  
• Activates the pathogen resistance response defense  
• Induces senescence in already-damaged cells and their proximate neighbors  
• ABA is generated to control seed germination and further developmental 
processes and as a signaling molecule to induce plant response to abiotic 
stresses such as salt, cold, drought, and wounding.  It quickly puts a plant, 
organ, tissue or individual cell in a defensive posture (whatever this entails) in 
response to rapidly-developing nutrient or environmental stress that threatens 
their survival.  
• Decreases metabolism in response to a newly-developing deficiency of 
nutrient or adverse environmental condition, such that the condition becomes 
survivable at the new lower level of metabolism. 
• Possibly induces cell dormancy or senescence by a climactic increase or 
sustained level, stimulating the synthesis of gibberalic acid and/or ethylene. 
• A climatic rise or sustained level of ABA may be a prerequisite for the 
synthesis of any gibberallic acid and/or ethylene in that its presence indicates 
unusable or unsurvivable levels of Water, Sugar, Minerals and/or essential 
gases. 
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3.2.5 Abscisic Acid – Biological significance and pharmacological role  
Recent studies of some phytohormones both in-vivo and in-vitro has opened a new 
door to work-out new leading chemical entities in the field of pharmacology. The 
most promising among these plant hormones is abscisic acid. Following are some 
reported information which claims the possible role of abscisic acid as a 
pharmacological molecule and its therapeutic usefulness: 
1. ABA was reported to stimulate several functional activities (phagocytosis, 
reactive oxygen species and nitric oxide (NO) production, and chemotaxis) of 
human granulocytes through a signaling pathway sequentially involving a 
pertussis toxin (PTX)-sensitive G protein/receptor complex, protein kinase A 
activation, ADP-ribosyl cyclase phosphorylation, and consequent cyclic-ADP-
ribose overproduction, leading to an increase of the intracellular Ca+2 
concentration. The increase of free intracellular ABA and its release by 
activated human granulocytes indicated that ABA should be considered as a 
new pro-inflammatory cytokine in humans. ABA behaves as a pro-
inflammatory endogenous cytokine capable of stimulating granulocyte 
functions (N. LeBrasseur, 2007; Bruzzone, 2007). 
2. ABA (free and conjugated) has been detected in the brain of mammals (Le 
Page-Degivry, 1986). 
3. ABA could be used as a nutritional intervention against type II diabetes and 
obesity-related inflammation (Guri et al., 2006). PPAR γ -responsive genes 
were found to be induced or activated by abscisic acid in 3T3-L1 
preadipocytes in vitro (Guri et al., 2008; Lehmann et al., 1995). ABA is 
produced by pancreatic islets and acts as an endogenous insulin secretor at 
nanomolar concentrations with cyclic ADP ribose as second messenger 
(Bruzzone et al., 2008). 
4. ABA intake exerted an anti-atherosclerotic and anti-hypertensive effect in 
ApoE-/- mice by suppressing macrophage and CD4+ T cell infiltration into the 
aortic walls (Guri et al., 2009). 
5. A patent was issued to Livingston-Wheeler in 1976 for its use as an anti-
cancer compound (Livingston, 1976). The patent describes the use of a solid 
myeloid leukemia C1498 transplantation model in C57BL/6 mice to 
investigate the anti-cancer efficacy of ABA. The inventor reported increased 
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survival rates at 14 days posttransplantation in mice treated with ABA in 
comparison to control mice. The inventor also proposed that ABA 
“neutralized” the human chorionic gonadotropin (hCG) that report. Role of 
abscisic acid as an anti-cancer drug has also been claimed by Ann Wigmore 
(Wigmore, 1985). 
6. ABA was reported to inhibit proliferation and induced differentiation in 
human SMMC-7221 cells (Ma et al., 2006) and in nude mice transplanted with 
human hepatocarcinoma (Lu et al., 2007). Tan et al. (2006) reported in a 
China patent that ABA effectively inhibits the proliferation of tumour cells; 
stagnates the cells in S phase, stops cell division, and induces differentiation of 
tumour cells or reverts cancerous cells to normal cells. 
7. ABA has a profound effect on some mammalian tissues and on a 
cyanobacterium. Studies on smooth muscles from the vas deferens and bladder 
of rat showed that 10-6M ABA enhanced field stimulation responses by about 
25%. This effect was inhibited by the calcium-channel blocker, nifedipine. In 
K+-depolarized bladder smooth muscle in which the fast calcium channels 
were voltage-inactivated, 10-6M ABA augmented contracture tension, and 
enhanced the slow tonic phase of the response which is known to be 
dependent on the activity of slow calcium channels (Huddart et al., 1986). 
8. Masters et al. (1994) reported that ABA is without significant Ca+2 modulatory 
activity in rat prostatic and epididymal vas deferens smooth muscle 
preparation but the ABA analogue SD217595 possesses strong Ca+2 entry 
blocking ability. Lynch et al. (1991) also reported that abscisic acid (ABA) 
analogue SD217595 inhibits K+-induced phasic and tonic contractions of rat 
bladder detrusor smooth muscle strips. 
9. Magnone et al. (2009) reported ABA increases NF-κβ activation and MCP-1 
secretion in cultured human monocytes. 
10. ABA induced a significant increase in prostaglandin E2 (PGE2) production, 
induced chemokinesis or cell migration and stimulated the release of several 
cytokines known to mediate the trophic and immunomodulatory properties of 
mesenchymal stem cells (MSC). In MSC, ABA production and release were 
stimulated by specific growth factors (e.g., bone morphogenetic protein-7), by 
inflammatory cytokines, and by lymphocyte conditioned medium (Scarfi et al., 
2008). 
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11. United States Patent-3958025: “Tablets of abscisic acid and a carrier are used 
to treat a vitamin deficiency of abscisic acid in man, animal and the avian 
species” is also been filed (www.freepatentsonline.com). 
12. It was observed that abscisic acid apparently is non-toxic in the mouse even 
when administered I.P. in amounts of up to 10% by weight of the mouse 
(www.freepatentsonline.com). 
13. Guri et al. (2010) reported that ABA prevents experimental inflammatory 
bowel disease (IBD). ABA significantly ameliorated disease activity, colitis 
and reduced colonic leukocyte infiltration and inflammation. These 
improvements were associated with the decreased expression of VCAM-1, E-
selectin, and mucosal addressin adhesion marker-1. ABA also increased the 
numbers of CD4 and CD8 T-lymphocytes in the blood as well as MLN and 
regulatory T cells in the blood. 
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3.3 Insulin resistance 
3.3.1 Diabetes mellitus  
Diabetes mellitus (DM) comprises a group of common metabolic disorders that share 
the phenotype of hyperglycemia. Several distinct types of DM exist and are caused by 
a complex interaction of genetics, environmental factors, and life-style choices. 
Depending on the etiology of the DM, factors contributing to hyperglycemia may 
include reduced insulin secretion, decreased glucose utilization, and increased glucose 
production. The defect in metabolic regulation associated with DM causes secondary 
pathophysiological changes in multiple organ systems that impose a tremendous 
burden on the individual with diabetes and on the health care system. In the United 
States, DM is the leading cause of end-stage renal disease (ESRD), non-traumatic 
lower extremity amputations, and adult blindness. With an increasing incidence 
worldwide, DM will be a leading cause of morbidity and mortality for the foreseeable 
future. 
3.3.1.1 Classification  
DM is classified on the basis of the pathogenic process that leads to hyperglycemia, as 
opposed to earlier criteria such as age of onset or type of therapy. The two broad 
categories of DM are designated type 1 and type 2. Type 1A DM results from 
autoimmune beta cell destruction, which leads to insulin deficiency. Individuals with 
type 1B DM lack immunologic markers indicative of an autoimmune destructive 
process of the beta cells (Atkinson and Maclaren, 1994). However, they develop 
insulin deficiency by unknown mechanisms and are ketosis prone (Maclaren et al., 
1988). Type 2 DM is a heterogeneous group of disorders characterized by variable 
degrees of insulin resistance, impaired insulin secretion, and increased glucose 
production. Previously the terms insulin-dependent diabetes mellitus (IDDM) and non 
insulin-dependent diabetes mellitus (NIDDM) were used for type-1 and type-2 DM, 
which are now obsolete. Since many individuals with type 2 DM eventually require 
insulin treatment for control of glycemia, the use of the term NIDDM generated 
considerable confusion. 
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Etiological Classification: (Kasper et al., 2005) 
1. Type 1 diabetes mellitus ( formerly IDDM) 
 Autoimmune type 1 diabetes mellitus (type 1 A) 
 Non-autoimmune or idiopathic type 1 diabetes mellitus (type 1 B) 
2. Type 2 diabetes mellitus (formerly NIDDM) 
3. Other specific types  
 Specific defined gene mutations 
 Maturity onset diabetes of the youth (MODY) 
  MODY 1 hepatic nuclear factor 4α gene mutations 
  MODY 2 glucokinase gene mutations 
  MODY 3 hepatic nuclear factor 1α gene mutations 
  MODY 4 pancreatic determining factor X gene mutations 
  MODY X unidentified gene mutations  
 Maternally inherited diabetes and deafness (MIDD) 
  Mitochondrially leucine t RNA gene mutations  
  Insulin gene mutations 
  Insulin receptor gene mutations 
 Secondary to pancreatic diseases 
  Chronic pancreatitis 
  Tropical diabetes 
  Neoplasia 
  Pancreatectomy 
 Secondary to endocrinopathies 
  Acromegaly 
  Cushing’s syndrome 
  Glucagonoma 
  Pheochromocytoma 
  Hyperthyroidism 
 Secondary to immune suppression 
 Due to infections 
  Congenital rubella 
  Cytomegalo virus 
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Drug or chemical induced diabetes 
  Glucocorticoids  
  Diuretics 
  Diazoxide 
  Ca+2-channel blockers 
  β2-adrenergic receptors agonists 
  Phenytoin 
  α-interferons 
  Clonidine 
  Thyroid hormones, etc. 
3.3.1.2 Pathogenesis  
3.3.1.2.1 Type 1 DM 
Type 1A DM develops as a result of the synergistic effects of genetic, environmental, 
and immunologic factors that ultimately destroy the pancreatic beta cells. Individuals 
with a genetic susceptibility have normal beta cell mass at birth but begin to lose beta 
cells secondary to autoimmune destruction that occurs over months to years. This 
autoimmune process is thought to be triggered by an infectious or environmental 
stimulus and to be sustained by a beta cell–specific molecule. In the majority of 
individuals, immunologic markers appear after the triggering event but before 
diabetes become clinically overt. Β-cell mass then begins to decline, and insulin 
secretion becomes progressively impaired, although normal glucose tolerance is 
maintained. Features of diabetes do not become evident until a majority of beta cells 
are destroyed (>80%) (Maclaren et al., 1988). At this point, residual functional beta 
cells still exist but are insufficient in number to maintain glucose tolerance. The 
events that trigger the transition from glucose intolerance to frank diabetes are often 
associated with increased insulin requirements, as might occur during infections or 
puberty. After the initial clinical presentation of type 1A DM, a “honeymoon” phase 
may ensue during which time glycemic control is achieved with modest doses of 
insulin or, rarely, insulin is not needed. However, this fleeting phase of endogenous 
insulin production from residual beta cells disappears as the autoimmune process 
destroys the remaining beta cells, and the individual becomes completely insulin 
deficient. 
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3.3.1.2.2 Type 2 DM 
Insulin resistance and abnormal insulin secretion are central to the development of 
type 2 DM. Although controversy remains regarding the primary defect, most studies 
support the view that insulin resistance precedes insulin secretory defects and that 
diabetes develops only if insulin secretion becomes inadequate. 
3.3.1.2.2.1 Metabolic Abnormalities- Insulin Resistance 
The decreased ability of insulin to act effectively on peripheral target tissues 
(especially muscle and liver) is a prominent feature of type 2 DM and results from a 
combination of genetic susceptibility and obesity (Umpierrez  et al.,1995; Dagogo-
Jack et al.,1997). Insulin resistance is relative, however, since supernormal levels of 
circulating insulin will normalize the plasma glucose. Insulin dose-response curves 
exhibit a rightward shift, indicating reduced sensitivity, and a reduced maximal 
response, indicating an overall decrease in maximum glucose utilization (30 to 60% 
lower than normal individuals). Insulin resistance is believed to play a major role in 
its pathogenesis, causing progressive β-cell dysfunction (Polonsky  et al .,1996 ; 
Haffner  et al.,1990; Warram  et al.,1990; Lillioja et al.,1993). 
Insulin resistance impairs glucose utilization by insulin-sensitive tissues and increases 
hepatic glucose output; both effects contribute to the hyperglycemia. Increased 
hepatic glucose output predominantly accounts for increased FPG levels, whereas 
decreased peripheral glucose usage results in postprandial hyperglycemia. In skeletal 
muscle, there is a greater impairment in nonoxidative glucose usage (glycogen 
formation) than in oxidative glucose metabolism through glycolysis. Glucose 
metabolism in insulin-independent tissues is not altered in type 2 DM. The precise 
molecular mechanism of insulin resistance in type 2 DM has not been elucidated. 
Insulin receptor levels and tyrosine kinase activity in skeletal muscle are reduced, but 
these alterations are most likely secondary to hyperinsulinemia and are not a primary 
defect. Therefore, postreceptor defects are believed to play the predominant role in 
insulin resistance. Polymorphisms in IRS-1 may be associated with glucose 
intolerance, raising the possibility that polymorphisms in various postreceptor 
molecules may combine to create an insulin-resistant state. The pathogenesis of 
insulin resistance is currently focused on a PI-3-kinase signaling defect, which 
reduces translocation of GLUT4 to the plasma membrane, among other abnormalities. 
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Of note, not all insulin signal transduction pathways are resistant to the effects of 
insulin [e.g., those controlling cell growth and differentiation and using the mitogen-
activated protein (MAP) kinase pathway]. Consequently, hyperinsulinemia may 
increase the insulin action through these pathways, potentially accelerating diabetes-
related conditions such as atherosclerosis. Another emerging theory proposes that 
elevated levels of free fatty acids, a common feature of obesity, may contribute to the 
pathogenesis of type 2 DM (Prentki et al., 1996; Shimabukuro et al., 1998). Free fatty 
acids can impair glucose utilization in skeletal muscle, promote glucose production by 
the liver, and impair beta cell function. 
 Insulin Resistance Syndrome 
The insulin resistance condition comprises a spectrum of disorders, with 
hyperglycemia representing one of the most readily diagnosed features. The metabolic 
syndrome, the insulin resistance syndrome, or syndrome X are terms used to describe 
a constellation of metabolic derangements that includes insulin resistance, 
hypertension, dyslipidemia [low high-density lipoprotein (HDL) and elevated 
triglycerides], central or visceral obesity, type 2 diabetes or IGT/IFG, and accelerated 
cardiovascular disease (Saltiel and Kahn, 2001). Insulin resistance is a serious 
medical problem that leads to type 2 diabetes when pancreatic β-cells fail to 
compensate by increasing the amount of secreted insulin (DeFronzo, 1997). 
At the physiological level, obesity, inactivity, and aging are common causes of insulin 
resistance. Although moderate compensatory hyperinsulinemia might be well 
tolerated in the short term, chronic hyperinsulinemia exacerbates insulin resistance 
and contributes directly to β-cell failure and diabetes (Pessin et al., 2000; Shulman, 
2000). Importantly, the β-cell failure probably does not arise from overwork but rather 
from dysregulated growth and survival signals that accompany insulin resistant states. 
 Symptoms of metabolic syndrome 
Many people are unaware that they have metabolic syndrome (Syndrome X), even 
though the American Heart Association estimates that 20-25% of the adult population 
of the U.S. suffers from this disorder – between 58 and 73 million men and women. 
Metabolic Syndrome is characterized by having at least three of the following 
symptoms: 
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• Insulin Resistance (when the body can’t absorb blood sugar or insulin 
properly)  
• Abdominal fat – in men this means a 40 inch waist or larger, in women 35 
inches or larger  
• High blood sugar levels – at least 110 milligrams per deciliter (mg/dL) 
after fasting  
• High triglycerides – at least 150 mg/dL in the blood stream  
• Low HDL (the “good” cholesterol) – less than 40 mg/dL  
• Pro-thrombotic state (e.g. high fibrinogen or plasminogen activator 
inhibitor in the blood)  
• Blood pressure of 130/85 mmHg or higher 
The American Heart Association states that the “underlying causes of Metabolic 
Syndrome are being overweight, physical inactivity and genetic factors.” Researchers 
have found a connection between Metabolic Syndrome and other conditions such as 
obesity, high blood pressure and high levels of LDL “bad” cholesterol, all of which 
are risk factors for Cardiovascular Disease. Studies have shown, for example, an 
increased link between Metabolic Syndrome and atherosclerosis, which occurs when 
fatty deposits called plaque cling to the interior walls of the arteries, leading to 
blockages that can cause heart attacks or stroke. People with Metabolic Syndrome are 
also more prone to developing Type 2 Diabetes, as well as PCOS (Polycystic Ovarian 
Syndrome) in women and prostate cancer in men. All these findings substantially 
raise the bar on the seriousness of Metabolic Syndrome, making it even more 
important that doctors correctly diagnose the condition and instruct their patients 
about one of its underlying causes – Insulin Resistance. At present, there is no single 
pharmaceutical drug that can reverse the symptoms of Metabolic Syndrome. A 
complete system of elements is needed to treat the major factor in causing this 
condition, namely Insulin Resistance. 
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3.3.1.3 Treatment 
Table – 3.1: Oral Glucose-Lowering Therapies in Type 2 DM 
(UKPDS, 1998; American diabetes association, 2002) 
 Mechanism of Action Examples 
 
Agent-
Specific 
Advantage 
 
Agent-Specific 
Disadvantages 
 
 
Contraindications 
Insulin 
secretagogues 
↑ Insulin 
secretion     
(a)Sulfonylureas  
Tolbutamide 
Glimepiride 
Glipizide 
Glyburide 
Lower fasting 
blood glucose 
Hypoglycemia 
weight gain, 
hyperinsulinemia 
Renal/liver disease 
(b) Meglitinide  Repaglinide 
Short onset of 
action, lower 
postprandial 
glucose 
Hypoglycemia Liver disease 
Biguanides 
(Kirpichnikov, 
2002; Knowler, 
2002) 
↓Hepatic 
glucose 
production, 
weight loss, 
↑glucose 
utilization 
Metformin 
Weight loss, 
improved 
lipid profile, 
no 
hypoglycemia 
Lactic acidosis, 
diarrhea, nausea, 
possible 
increased 
cardiovascular 
mortality 
Serum creatinine 
>1.5 mg/dL (men), 
>1.4 mg/dL 
(women), 
radiographic 
contrast studies, 
seriously ill 
patients, acidosis 
α-Glucosidase 
inhibitors 
↓Glucose 
absorption 
Acarbose, 
miglitol 
No risk of 
hypoglycemia 
GI flatulence, 
↑liver function 
tests 
Liver/renal disease 
Thiazolidinediones 
↓Insulin 
resistance, 
↑glucose 
utilization 
Rosiglitazone, 
pioglitazone 
↓Insulin and 
sulfonylurea 
requirements, 
↓triglycerides 
Frequent hepatic 
monitoring for 
idiosyncratic 
hepatocellular 
injury (see text) 
Liver disease, 
congestive heart 
failure 
Medical nutrition 
therapy and 
physical activity    
(Clement, 2004) 
↓Insulin 
resistance 
Low-calorie, 
low-fat diet, 
exercise 
Other health 
benefits 
Compliance 
difficult, long-
term success low 
 
 
Type 1 DM is treated with Insulin whereas in type 2 DM oral hypoglycemic agents 
are used. The table-3.1 shows the whole treatment regimen for insulin resistance 
(Type 2 DM). 
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3.3.2 Abscisic acid and insulin resistance 
PPAR-γ agonists, such as thiazolidinediones (TZDs), have been shown to be very 
effective in improving systemic insulin sensitivity. Abscisic acid is structurally 
similar to TZDs. It is found that ABA could be used as a nutritional supplement to 
combat type II diabetes and obesity-related inflammation (Guri et al., 2007). Dietary 
ABA-increased mRNA expression was found to increase the expression of PPAR-γ 
and its responsive genes (i.e., adiponectin, aP2, and CD36) in WAT. No side effects 
were observed in ABA-fed mice, such as excess weight gain and fluid retention, 
which are commonly observed with TZDs (Guri et al., 2007). Moreover, PPAR γ -
responsive genes were found to be induced or activated by abscisic acid in 3T3-L1 
pre-adipocytes in vitro (Lehmann et al., 1995; Guri et al., 2008). ABA is also 
produced by pancreatic islets and acts as an endogenous insulin secretor at nanomolar 
concentrations with cyclic ADP ribose as second messenger (Bruzzone et al., 2008; 
Bassaganya-Riera et al., 2010). 
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3.4 Cancer 
Cancer (medical term: malignant neoplasm) is a class of diseases in which a group of 
cells display the traits of uncontrolled growth (growth and division beyond the normal 
limits), invasion (intrusion on and destruction of adjacent tissues), and sometimes 
metastasis (spread to other locations in the body via lymph or blood). These three 
malignant properties of cancers differentiate them from benign tumors, which are 
selflimited, do not invade or metastasize. Most cancers form a tumor but some, like 
leukemia, do not. (Fodde and Smits, 2002; Merlo et al., 2006) 
3.4.1 Pathways to cancer 
There are many distinct types of cancer, there are believed to be six essential 
alterations to normal cell physiology, which together define the progression of most 
human malignancies (Hanahan et al., 2000). 
(1) Self-sufficiency in growth signals 
Normal cell proliferation depends upon the presence of growth factors produced 
outside of the cell. However, one of the key characteristics of the tumor cell is its 
capacity for proliferation without dependence on external growth factors. Tumor cells 
may proliferate by either internal production of growth factors or by responding to 
levels of external growth factors not usually sufficient to produce proliferation in 
normal cells (Jin et al., 2005). 
(2) Insensitivity to antigrowth signals 
In normal tissue, the stability of the cell population is maintained by a host of signals 
and factors inhibiting cell proliferation and differentiation. For cancer cells to survive 
and replicate, these antigrowth signals must be avoided (Hanahan et al., 2000, Jin et 
al., 2005). 
(3) Tissue invasion and metastasis 
Up to 90% of cancer deaths are due to metastatic disease. Once cancer cells leave the 
primary tumor and travel through the body, the ability to invade and colonize distant 
sites to form metastases is dependent on acquiring the ability to overcome the normal 
suppressors of invasion (Hanahan et al., 2000). 
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(4) Limitless potential for replication 
Many, if not all, normal human cells are programmed to limit their own replication. 
However, for cells to form a potentially life-threatening tumor, the mechanisms that 
normally limit replication must be disrupted. For a tumor cell population to expand, it 
must develop unlimited replicative potential, effectively gaining "immortality’’. 
(5) Sustained angiogenesis 
In normal tissue, continued cell function is dependent on the availability of oxygen 
and nutrients and the removal of metabolic waste through the capillary beds. 
Angiogenesis, the process by which new blood vessels are formed, is not an inherent 
property of most cells in small, localized neoplasms. To develop into larger, 
potentially metastatic tumors, angiogenic ability must be acquired (Bergers et al., 
2003). 
(6) Evading apoptosis 
In normal tissue, the stability of the cell population is maintained through a process of 
programmed cell death, or apoptosis, which is latent in virtually all cell types 
throughout the body. Acquiring resistance to apoptosis is one of the key mechanisms 
by which cancer cells maintain proliferation and is thought to be a critical survival 
factor for the majority of tumors (Ghobrial et al., 2005). 
3.4.2 Treatment 
Cancer can be treated by surgery, chemotherapy, radiation therapy, immunotherapy, 
monoclonal antibody therapy or other methods. The choice of therapy depends upon 
the location and grade of the tumor and the stage of the disease, as well as the general 
state of the patient (performance status). A number of experimental cancer treatments 
are also under development. (Dolmans et al., 2003; Kumar et al., 2005)  
Complete removal of the cancer without damage to the rest of the body is the goal of 
treatment. Sometimes this can be accomplished by surgery, but the propensity of 
cancers to invade adjacent tissue or to spread to distant sites by microscopic 
metastasis often limits its effectiveness. The effectiveness of chemotherapy is often 
limited by toxicity to other tissues in the body. Radiation can also cause damage to 
normal tissue. (Kleinman and Liau, 2001) 
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Table – 3.2: Classification of currently available anticancer drugs 
Alkylting agents Nitrogen mustards: Chlorambucil, Chlormethine, Cyclophosphamide, 
Ifosfamide, Melphalan, Bendamustine  
Nitrosoureas : Carmustine, Fotemustine, Lomustine, Streptozocin 
Platinum: Carboplatin, Cisplatin, Oxaliplatin, Triplatin tetranitrate 
Alkyl sulfonates: Busulfan, Treosulfan 
Hydrazines: Procarbazine, Dacarbazine, Temozolomide 
Aziridines : ThioTEPA 
Anti-metabolites Folic acid: Aminopterin, Methotrexate, Pemetrexed, Raltitrexed 
Purine: Cladribine, Clofarabine, Fludarabine, Mercaptopurine, 
Pentostatin, Thioguanine 
Pyrimidine: Capecitabine, Cytarabine, Decitabine, Fluorouracil,  
Mitotic inhibitor Taxane: Docetaxel, Larotaxel, Paclitaxel 
Vinca: Vinblastine, Vincristine, Vindesine, Vinorelbine 
Cytotoxic 
antibiotics 
Anthracycline family: Daunorubicin, Doxorubicin, Epirubicin, 
Idarubicin, Mitoxantrone, Pixantrone, Valrubicin 
Streptomyces: Actinomycin, Bleomycin, Mitomycin 
Topoisomerase 
inhibitors 
Camptotheca: Camptothecin, Irinotecan, Rubitecan 
 Podophyllum: Etoposide, Teniposide 
Monoclonal 
antibodies 
Receptor tyrosine kinase: Cetuximab, Panitumumab, Trastuzumab 
CD20: Rituximab, Tositumomab 
Other:  Alemtuzumab, Bevacizumab, Gemtuzumab 
Photosensitizers Aminolevulinic acid, Methyl aminolevulinate, Porfimer sodium, 
Verteporfin 
Tyrosine kinase 
inhibitors 
Axitinib, Bosutinib, Cediranib, Dasatinib, Erlotinib, Gefitinib, 
Imatinib, Lapatinib, Lestaurtinib, Nilotinib, Semaxanib, Sorafenib, 
Sunitinib, Vandetanib 
Retinoids Alitretinoin, Tretinoin 
Others Fusion protein (Aflibercept) - Altretamine, Amsacrine, Anagrelide, 
Arsenic trioxide, Asparaginase (Pegaspargase), Bexarotene, 
Bortezomib, Celecoxib, Denileukin diftitox, Elesclomol, Estramustine, 
Irofulven, Ixabepilone, Masoprocol, Mitotane, Oblimersen, 
Testolactone, Tipifarnib, Trabectedin 
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3.4.3 Breast cancer 
Breast cancer is a cancer that starts in the cells of the breast. Worldwide, breast cancer 
is the second most common type of cancer after lung cancer (10.4% of all cancer 
incidence, both sexes counted) and the fifth most common cause of cancer death. The 
most common pathologic types of breast cancer are invasive ductal carcinoma, 
malignant cancer in the breast's ducts, and invasive lobular carcinoma, malignant 
cancer in the breast's lobules. Breast is composed of identical tissues in males and 
females, breast cancer also occur in males. Incidences of breast cancer in men are 
approximately 100 times less common than in women, but men with breast cancer are 
considered to have the same statistical survival rates as women. No etiology is known 
for 95% of breast cancer cases, while approximately 5% of new breast cancers are 
attributable to hereditary syndromes. In particular, carriers of the breast cancer 
susceptibility genes, BRCA1 and BRCA2, are at a 30-40% increased risk for breast 
and ovarian cancer, depending on in which portion of the protein the mutation occurs. 
Breast cancer screening is an attempt to find unsuspected cancers. The most common 
screening methods are self and clinical breast exams, X-ray mammography, and 
breast Magnetic resonance imaging (MRI). (Paull et al., 2001) 
BRCA1 (breast cancer 1, early onset) is a human gene that belongs to a class of 
genes known as tumor suppressors, which maintains genomic integrity to prevent 
uncontrolled proliferation. The multifactorial BRCA1 protein product is involved in 
DNA damage repair, ubiquitination, transcriptional regulation as well as other 
functions. Variations in the gene have been implicated in a number of hereditary 
cancers, namely breast, ovarian and prostate. The BRCA1 gene is located on the long 
(q) arm of chromosome 17 at band 21, from base pair 38,449,843 to base pair 
38,530,933 (map). (Starita and Parvin, 2003) 
 DNA Damage Repair 
The BRCA1 protein is directly involved in the repair of damaged DNA. In the 
nucleus of many types of normal cells, the BRCA1 protein is thought to interact with 
RAD51 during repair of DNA double-strand breaks, though the details and 
significance of this interaction is the subject of debate. These breaks can be caused by 
natural radiation or other exposures, but also occur when chromosomes exchange 
genetic material during a special type of cell division that creates sperm and eggs 
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(meiosis). The BRCA2 protein, which has a function similar to that of BRCA1, also 
interacts with the RAD51 protein. By influencing DNA damage repair, these three 
proteins play a role in maintaining the stability of the human genome. 
BRCA1 directly binds to DNA, with higher affinity for branched DNA structures. 
This ability to bind to DNA contributes to its ability to inhibit the nuclease activity of 
the MRN complex as well as the nuclease activity of Mre11 alone. This may explain a 
role for BRCA1 to promote higher fidelity DNA repair by NHEJ. BRCA1 also 
colocalizes with γ-H2AX (histone H2AX phosphorylated on serine-139) in DNA 
double-strand break repair foci, indicating it may play a role in recruiting repair 
factors. (Paull et al., 2001; Durant and Nickoloff, 2005) 
 Transcription 
BRCA1 was shown to co-purify with the human RNA Polymerase II holoenzyme in 
HeLa extracts, implying it is a component of the holoenzyme. Later research, 
however, contradicted this assumption, instead showing that the predominant complex 
including BRCA1 in HeLa cells is a 2 megadalton complex containing SWI/SNF. 
SWI/SNF is a chromatin remodeling complex. Artificial tethering of BRCA1 to 
chromatin was shown to decondense heterochromatin, though the SWI/SNF 
interacting domain was not necessary for this role. BRCA1 interacts with the NELF-B 
(COBRA1) subunit of the NELF complex. (Ye et al., 2001) 
  Other roles 
Research suggests that both the BRCA1 and BRCA2 proteins regulate the activity of 
other genes and play a critical role in embryo development. The BRCA1 protein 
probably interacts with many other proteins, including tumor suppressors and 
regulators of the cell division cycle. 
 Mutations and Cancer Risk 
Certain variations of the BRCA1 gene lead to an increased risk for breast cancer. 
Researchers have identified more than 600 mutations in the BRCA1 gene, many of 
which are associated with an increased risk of cancer. These mutations can be changes 
in one or a small number of DNA base pairs (the building blocks of DNA). Those 
mutations can be identified with PCR and DNA sequencing. 
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In some cases, large segments of DNA are rearranged. Those large segments, also 
called large rearrangements, can be a deletion or a duplication of one or several axons 
in the gene. Classical methods for mutations detection (sequencing) are unable to 
reveal those mutations. Other methods are proposed: Q-PCR. Multiplex Ligation-
dependent Probe Amplification (MLPA), and Quantitative Multiplex PCR of Shorts 
Fluorescents Fragments (QMPSF). New methods have been recently proposed: 
heteroduplex analysis (HDA) by multi-capillary electrophoresis or also dedicated 
oligonucleotides array based on comparative genomic hybridization (array-CGH). 
(Tapia et al., 2008) 
A mutated BRCA1 gene usually makes a protein that does not function properly 
because it is abnormally short. Researchers believe that the defective BRCA1 protein 
is unable to help fix mutations that occur in other genes. These defects accumulate 
and may allow cells to grow and divide uncontrollably to form a tumor. In addition to 
breast cancer, mutations in the BRCA1 gene also increase the risk of ovarian, fallopian 
tube and prostate cancers. Moreover, precancerous lesions (dysplasia) within the 
fallopian tube have been linked to BRCA1 gene mutations. (Hogervorst et al., 2003) 
BRCA2 (Breast Cancer Type 2 susceptibility protein) is a human gene that is 
involved in the repair of chromosomal damage and belongs to a class of genes known 
as tumor suppressor genes. Tumor suppressor genes regulate the cycle of cell division 
by keeping cells from growing and dividing too rapidly or in an uncontrolled way. 
Although the structures of the BRCA1 and BRCA2 genes are very different, their 
functions appear to be similar. The proteins made by both genes are essential for 
repairing damaged DNA. The BRCA2 protein binds to and regulates the protein 
produced by the RAD51 gene to fix breaks in DNA. These breaks can be caused by 
natural and medical radiation or other environmental exposures, but also occur when 
chromosomes exchange genetic material during a special type of cell division that 
creates sperm and eggs (meiosis). The BRCA1 protein also interacts with the RAD51 
protein. By repairing DNA, these three proteins play a role in maintaining the stability 
of the human genome. Like BRCA1, BRCA2 probably regulates the activity of other 
genes and plays a critical role in embryo development. The BRCA2 gene is located on 
the long (q) arm of chromosome 13 at position 12.3 (13q12.3), from base pair 
31,787,616 to base pair 31,871,804. (Orelli and Bishop, 2001) 
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 Related conditions 
Certain variations of the BRCA2 gene cause an increased risk for breast cancer. 
Researchers have identified about 450 mutations in the BRCA2 gene, many of which 
cause an increased risk of cancer. BRCA2 mutations are usually insertions or 
deletions of a small number of DNA base pairs (the building material of 
chromosomes) in the gene. As a result of these mutations, the protein product of the 
BRCA2 gene is abnormally short and does not function properly. Researchers believe 
that the defective BRCA2 protein is unable to help fix mutations that occur in other 
genes. As a result, mutations build up and can cause cells to divide in an uncontrolled 
way and form a tumor. (Zou et al., 1999) 
People who have two mutated copies of the BRCA2 gene have one type of Fanconi 
anemia. This condition is caused by extremely reduced levels of the BRCA2 protein 
in cells, which allows the accumulation of damaged DNA. Patients with Fanconi 
anemia are prone to several types of leukemia (a type of blood cell cancer); solid 
tumors, particularly of the head, neck, skin, and reproductive organs; and bone 
marrow suppression (reduced blood cell production that leads to anemia). In addition 
to breast cancer in men and women, mutations in BRCA2 also lead to an increased 
risk of ovarian, Fallopian tube, prostate, and pancreatic cancers, as well as malignant 
melanoma. In some studies, mutations in the central part of the gene have been 
associated with a higher risk of ovarian cancer and a lower risk of prostate cancer than 
mutations in other parts of the gene. Several other types of cancer have also been seen 
in certain families with BRCA2 mutations. (Yoshida et al., 2004) 
 Discovery of BRCA2 
The BRCA2 gene was discovered in 1995 by Professor Michael Stratton and Dr. 
Richard Wooster (Institute of Cancer Research, UK). The Wellcome Trust Sanger 
Institute (Hinxton, Cambs, UK) collaborated with Stratton and Wooster to isolate the 
gene. In honour of this discovery and collaboration, the Wellcome Trust has 
participated in the construction of a cycle path between Addenbrooke's Hospital site 
in Cambridge and the nearby village of Great Shelford. It is decorated with over 
10,000 lines of 4 colours representing the nucleotide sequence of BRCA2. It makes-
up part of the National Cycle Network route 11, and can be seen from the Cambridge-
London Liverpool Street train. (Duncan et al., 1998) 
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Figure 3.1: Location of gene BRCA1 on chromosome 17 and  
BRCA2 on chromosome 13 (Zou et al., 1999) 
Statistics show that the incidence of breast cancer is rapidly increasing in urban India 
and has overtaken cancer of the cervix as the number one cancer in our major metros 
according to a study conducted on women and cancer in India. 
The number of breast cancer cases is estimated to have reached 1.2 million 
worldwide. Snacking, fatty food, late marriage and delayed motherhood are some 
factors that can lead to a high risk of breast cancer. It is now clear that in 
postmenopausal women an enzyme called aromatase present in peripheral tissues such 
as fat, muscle and liver produces oestrogen that triggers breast cancer. 
3.4.4 Cell line and its role in in-vitro screening method 
3.4.4.1 Cell line 
Specific cells that can grow indefinitely given the appropriate medium and conditions 
i.e. living cells that are maintained in vitro in artificial media of serum and nutrients 
for the study and growth of certain strains, experiments in controlling diseases, or 
study of the reaction to certain drugs or agents (Walton et al., 1975). Human tumor 
cell line panels combined with rapid high-throughput cytotoxicity testing have proven 
to be valuable tools for drug screening and early drug evaluation and investigation of 
drug resistance mechanisms. The National Cancer Institute (NCI) pioneered the 
utilization of large human tumor cell line panels for drug screens, after phasing out 
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their previously used animal models. The disease-oriented cell line panel used by NCI 
consists of 60 different cell lines, which consists of seven sub panels representing 
common solid tumors, leukemia and lymphomas (Shoemaker et al., 1988; Suggitt and 
Bibby, 2005). To date, more than 100 000 compounds and a large number of natural 
product extracts have been tested in their short-term growth inhibition assay 
(Shoemaker et al., 1988; Bussey et al., 2006). Typically, compounds are applied to the 
cell lines in a wide concentration range, and concentrations that inhibit/kill e.g. 50 % 
of the cells (IC50) are determined. The IC50 concentrations for a drug in many cell 
lines provide a drug specific profile, which can be compared to profiles from other 
drugs. This approach has successfully been used for drug mechanism classification of 
standard drugs, and assignment of drug action to investigational drugs and discovery 
of new classes of chemotherapeutic compounds (Dhar et al., 1996; Paull et al., 1989; 
Weinstein et al., 1997). 
3.4.4.2 Concepts in mammalian cell culture 
 Isolation of cells 
Cells can be isolated from tissues for ex vivo culture in several ways. Cells can be 
easily purified from blood; however only the white cells are capable of growth in 
culture. Mononuclear cells can be released from soft tissues by enzymatic digestion 
with enzymes such as collagenase, trypsin, or pronase, which break down the 
extracellular matrix. Alternatively, pieces of tissue can be placed in growth media, 
and the cells that grow out are available for culture. This method is known as explant 
culture. 
Cells that are cultured directly from a subject are known as primary cells. With the 
exception of some derived from tumours, most primary cell cultures have limited 
lifespan. After a certain number of population doublings cells undergo the process of 
senescence and stop dividing, while generally retaining viability (Freshney, 2005). 
An established or immortalized cell line acquire the ability to proliferate indefinitely 
either through random mutation or deliberate modification, such as artificial 
expression of the telomerase gene. There are numerous well established cell lines 
representative of particular cell types (Walton et al., 1975). 
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  Maintaining cells in culture 
Cells are grown and maintained at an appropriate temperature and gas mixture 
(typically, 37°C, 5% CO2) in a cell incubator. Culture conditions vary widely for each 
cell type and variation of conditions for a particular cell type can result in different 
phenotypes being expressed. 
Aside from temperature and gas mixture, the most commonly varied factor in culture 
systems is the growth medium. Recipes for growth media can vary in pH, glucose 
concentration, growth factors, and the presence of other nutrient components. The 
growth factors used to supplement media are often derived from animal blood, such as 
calf serum. These blood-derived ingredients pose the potential for contamination of 
derived pharmaceutical products with viruses or prions. Current practice is to 
minimize or eliminate the use of these ingredients where possible. Some cells 
naturally live without attaching to a surface, such as cells that exist in the 
bloodstream. Others require a surface, such as most cells derived from solid tissues. 
Cells grown unattached to a surface are referred to as suspension cultures for 
example, U-937, HL60 etc. Other adherent cultures cells can be grown on tissue 
culture plastic, which may be coated with extracellular matrix components (e.g. 
collagen or fibronectin) to increase its adhesion properties and provide other signals 
needed for growth. Example of adherent cell lines are HEp-2, HEK-293, MCF-7 etc. 
(Suggitt and Bibby, 2005). 
 Manipulation of cultured cells 
As cells generally continue to divide in culture, they generally grow to fill the 
available area or volume. This can generate several issues (Roberts and Spoon, 1990): 
• Nutrient depletion in the growth media 
• Accumulation of apoptotic/necrotic (dead) cells. 
• Cell-to-cell contact can stimulate cell cycle arrest, causing cells to stop 
dividing known as contact inhibition. 
• Cell-to-cell contact can stimulate promiscuous and unwanted cellular 
differentiation. 
These issues can be dealt with using tissue culture methods that rely on sterile 
technique. These methods aim to avoid contamination with bacteria or yeast that will 
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compete with mammalian cells for nutrients and/or cause cell infection and cell death. 
Manipulations are typically carried out in a biosafety hood or laminar flow cabinet to 
exclude contaminating micro-organisms. Antibiotics can also be added to the growth 
media (Cabrera et al., 2006). Amongst the common manipulations carried out on 
culture cells are media changes, passaging cells, and transfecting cells. 
Table – 3.3: List of commonly used cell lines (Freshney, 2005) 
Cell line Meaning  Organism Origin tissue Morphology 
HEK-293 Human 
embryonic 
kidney 
Human Kidney 
(embryonic) 
Epithelium 
HeLa Henrietta Lacks Human Cervical cancer Epithelium 
CHO Chinese hamster 
ovary 
Hamster Ovary Epithelium 
MCF-10A Michigan Cancer 
Foundation 
Human Mammary gland Epithelium 
Peer --- Human T cell leukemia --- 
HL-60 Human leukemia Human Myeloblast Bloodcells 
A-549 --- Human Lung carcinoma  Epithelium 
Jurkat --- Human T-Cell Leukemia Blood cells 
HEp-2 Larynx Cells Human Larynx epithelial Epithelial 
and Adherent 
U-937 Histolytic 
lymphoma 
Human Monocytic 
Lymphoma 
Suspension 
(1) Media changes 
The purpose of media changes is to replenish nutrients and avoid the build up of 
potentially harmful metabolic byproducts and dead cells. In the case of suspension 
cultures, cells can be separated from the media by centrifugation and resuspended in 
fresh media. In the case of adherent cultures, the media can be removed directly by 
aspiration and replaced (MacLeod et al., 1999). 
(2) Passaging cells 
Passaging or sub culturing cell culture involves transferring a small number of cells 
into a new vessel. Cells can be cultured for a longer time if they are split regularly, as 
it avoids the senescence associated with prolonged high cell density. Suspension 
cultures are easily passaged with a small amount of culture containing a few cells 
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diluted in a larger volume of fresh media. For adherent cultures, cells first need to be 
detached; this was historically done with a mixture of trypsin-EDTA; however other 
enzyme mixes are now available for this purpose. A small number of detached cells 
can then be used to seed a new culture (Chatterjee, 2007). 
3.4.4.3 MCF-7 cell line: 
MCF-7 is a breast cancer cell line isolated in 1970 from a 69-year-old Caucasian 
woman. MCF-7 is the acronym of Michigan Cancer Foundation – 7, referring to the 
institute in Detroit where the cell line was established in 1973 by Herbert Soule and 
co-workers (Soule et al., 1973). The MCF-7 cell-lines retain several characteristics of 
differentiated mammary epithelium including ability to process estradiol via 
cytoplasmic estrogen receptors and the capability of forming domes. Growth of MCF-
7 cells is inhibited by tumor necrosis factor alpha (TNF-α). Treatment with anti-
estrogens can modulate the secretion of insulin-like growth factor binding proteins. 
MCF-7 and two other breast cancer cell lines, named T-47D, MDA-MB231, account 
for more than two-thirds of all abstracts reporting studies on mentioned BCC lines, as 
concluded from a Medline-based survey (Dickson et al., 1986; Osborne et al., 1987). 
PIK3CA helical mutations were identified in MCF-7, but with low AKT activation. 
The stem line chromosome numbers ranged from hypertriploidy to hypotetraploidy, 
with the 2S component occurring at 1%. There were 29 to 34 marker chromosomes 
per S metaphase; 24 to 28 markers occurred in at least 30% of cells, and generally one 
large submetacentric (M1) and 3 large subtelocentric (M2, M3, and M4) markers were 
recognizable in over 80% of metaphases. No DM was detected. Chromosome 20 was 
nullisomic and X was disomic (Dickson et al., 1986; Osborne et al., 1987). 
Characteristics 
Primary tumor    :  Invasive breast ductal carcinoma 
Origin of cells     :  Pleural effusion 
Presence of estrogen receptors          :  Yes 
Proliferative response to estrogens   :  Yes 
Presence of progesterone receptor :  Yes 
Phenotype     :  Luminal epithelial 
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Figure 3.2: MCF-7 cells under light microscope (10 X) 
3.4.4.4 MDA-MB-468 cell line: 
 
Figure 3.3: MDA-MB-468 cells under light microscope (10 X) 
Characteristics 
MDA-MB-468 cell line was isolated in 1977 by R. Cailleau et al. from a pleural 
effusion of a 51-year-old Black female patient with metastatic adenocarcinoma of the 
breast. Although the tissue donor was heterozygous for the G6PD alleles, the cell line 
consistently showed only the G6PD A phenotype. There is G -> A mutation in codon 
273 of the p53 gene resulting in an Arg -> His substitution (Avila et al., 1994). MDA-
MB-468 expresses receptors for epidermal growth factor (EGF) and transforming 
growth factor-α (TGF-α) (Bates et al., 1990). In vitro, the MDA-MB-468 cell line is 
commonly used in EGF signalling study. The cell line has abundant activity in both 
the chemo-invasion and chemotaxis assay. MDA-MB-468 cell line is an example of 
ER negative cell line. 
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3.4.5 In-vitro cytotoxicity assays 
To study cytotoxic activity of a compound, cytotoxic assays are carried out. It is now 
well-documented that apoptosis or programmed cell death is the key mechanism by 
which chemotherapeutic agents exert their cytotoxicity (Larson R., 2003). 
These assays are principally of two types. 
1. Radioactive and non-radioactive assays that measure increases in plasma 
membrane permeability, since dying cells become leaky. 
2. Colorimetric assays that measure reduction in the metabolic activity of 
mitochondria; mitochondria in dead cells cannot metabolize dyes, while 
mitochondria in live cells can metabolize it and so are distinguished. 
Depending on the knowledge of physiological events occurring in cell cycle and 
death, assay type is chosen and used. A number of methods have now been developed 
to study apoptosis in cell populations (Boyd, 1985). 
Cytotoxicity tests measure the concentration of the substance that damages 
components, structures or cellular biochemical pathways, and they also allow direct 
extrapolation of quantitative data to similar in vivo situations (Freshney, 2001; Bacon 
et al., 1990) This refers to the in vitro assessment of material to determine whether or 
not it releases toxic chemicals in sufficient quantities to kill cells either directly or 
indirectly through the inhibition of cell metabolic pathways. 
 Common Basic Steps of in-vitro Assays  
Although the techniques for testing drug sensitivities of tumor cells differ, each 
employ four common basic steps:  
i. Isolation of cells,  
ii. Incubation of cells with drugs,  
iii. Assessment of cell survival, and  
iv. Interpretation of the result (Brown and Markman, 1996)   
 Review of Literature 
[47] Devang B. Sheth 
 Ideal characteristics of in vitro methods (Gupta, 2003) 
• An ideal in vitro screening method should be simple economical, reproducible, 
rapid and sensitive. 
• The assay should be applicable to large number of tumor types and test 
compounds. 
• The choice of cell lines should be representative of clinical situation as close 
as possible. 
• The range of drug concentration used in vitro should be comparable to that 
expected for in vivo treatments. 
• The assay should be able to process a large number of samples quickly and in 
automated fashion. 
• Data acquisition should be simple, easily interpreted and applied. 
 Advantages 
The development of in-vitro cytotoxicity assays has been driven by the need  
• To rapidly evaluate the potential toxicity of large numbers of compounds,  
• To limit animal experimentation whenever possible, and  
• To carry out tests with small quantities of compound.  
• Most cost effective and easier to manage.  
The most promising advantage of in-vitro methods over in-vivo method is, here 
culture can be cultivated under a controlled environment (pH, temperature, humidity, 
oxygen carbon-dioxide balance etc.) resulting in homogeneous batches of cells and 
thus minimizing experimental errors. (Freshney, 2001; Gupta, 2003) 
 Limitation of in vitro methods: 
• They often furnish false positive results (compounds show no activity in vivo) 
and false negative results (compounds show no activity in vitro but show 
activity in vivo as they need to be biotransformed in vivo to pharmacologically 
active compounds). 
• A second pitfall is that role of pharmacokinetic in determining drug effects 
cannot be evaluated in vitro. 
• Geometry of solid tumors in vivo is very different from that of cells growing in 
vitro in suspension or mono layer culture. 
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3.4.5.1 Methodological Aspects 
The cell culture is a model of a target tissue in the human body and mimics the 
response of human cells to exposure to chemicals. Provided that time and degree of 
exposure (dosage for animals and concentration/ exposure time in cell tests) in the 
experiments correspond to human exposure, both models can potentially predict any 
type of chemical interference with corresponding aspects of the human body (Ekwall 
et al., 1990). In vitro Cell toxicity of chemicals can be predicted by observing few of 
changes as follows: 
(1) Morphological alteration: The first and most readily observed effect 
following exposure of cells to toxicants is morphological alteration in the cell 
layer and/or cell shape in monolayer culture. Therefore, it is not surprising that 
morphological alterations are used as an index of toxicity. Different types of 
toxic effects may require investigative tools of different levels of sensitivity. 
(Walton and Buckley, 1975) 
(2) Cell growth alteration: Another indicator of toxicity is altered cell growth. 
The effect of chemicals on the capability of cells to replicate is used as an 
index of toxicity; the concentration of the substances at which 50 per cent of 
the cells do not multiply is called the median inhibitory dose (ID50). A more 
specific measure of replication is plating efficiency-the ability of cells (100-
200 per dish, 60 mm diameter) to form colonies after 10-15 days of culture in 
the presence of a toxic agent gives more complete information, indicating both 
cell survival and ability to reproduce (Nardone, 1977). 
(3) Cell reproduction: Cell reproduction can be measured by several parameters 
including cell count, DNA content, protein content, or enzyme activity (e.g. 
ornithinedecarboxylase) (Costa, 1979). Each of these parameters can be 
measured by more or less sophisticated means. Examples are the assay of 
DNA content by biochemical methods and incorporation of radio labeled 
precursors. 
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Figure 3.4(a): Observations of viable and non viable cell under microscope, 
where viable cells appear as small, round and refractive while Non-viable cells appear 
as swollen, larger, and dark. 
 
Figure 3.4(b): Mechanism of dye exclusion, in which white colour live cell exclude 
dye and dark blue coloured dead cell allow dye to permeate 
(4) Cell viability: Another crude index of toxicity is cell viability measured by 
using vital dyes such as trypan blue which enters dead cells only or neutral red 
that is actively taken up by living cells; the latter is commonly used in 
biomaterial testing by the agar overlay method (Guess et at., 1965).A count of 
dead and vital cells in comparison with the control provides an index of 
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lethality of the test compound. The release of SlCr is another index of lethality 
measuring membrane functions (Holden et al., 1973). 
(5) Measurement of Biochemical or Metabolic cell alterations: Other indices 
of toxicity to basal cell functions involve measurement of biochemical or 
metabolic cell alterations. The pathways of energy transmission and their 
alterations, 2° consumption or ATP levels are usually measured by the Clark 
electrode (Harmon and Sanborn, 1982) and by the luciferase assay 
respectively. 
One parameter for cell death is the integrity of the cell membrane, which can be 
measured by the cytoplasmic enzyme activity released by damaged cells. Lactate 
dehydrogenase (LDH) is a stable cytoplasmic enzyme present in all cells. It is rapidly 
released into the cell culture supernatant upon damage of the plasma membrane. The 
LDH activity is determined in an enzymatic test. The first step is the reduction of 
NAD+ to NADH/H+ by the LDH catalyzed conversion of lactate to pyruvate. In a 
second step, the catalyst (diaphorase) transfers H/H+ from NADH/H+ to the 
tetrazolium salt 2-(4-iodophenyl) - 3-(4-nitrophenyl)-5-phenyltetrazolium chloride 
(INT), which is reduced to a red formazan (Elferink, 1979; Korzeniewski and 
Callewaert, 1983; Decker and Lohmann-Matthes, 1988; Lappalainen et al., 1994). 
Another parameter used as the basis for colorimetric assays is the metabolic activity 
of viable cells. Tetrazolium salts are reduced only by metabolically active cells. Thus, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) can be reduced 
to a blue colored formazan (Mosmann T, 1983). Table-3.4 represents various 
categories of viability assay and their principles. 
Drug exposure: 
Selection of drug concentrations for in vitro cytotoxic drug resistance assays is an 
important issue. There are at least three ways to approach the issue of appropriate 
drug exposure under assay conditions. One alternative is to find drug concentrations 
that mimic the in vivo situation, by means of comparison of intracellular uptake in 
vivo and in vitro (Sundman-Engberg B et al., 1990). A full concentration-effect curve 
can be aimed at, and the estimated IC50 value, can be used as the measure of activity 
(Fruehauf J and Bosanquet A, 1993). This will result in a better estimation of the 
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difference between resistant and sensitive samples, but for appropriate testing, an 
increased number of cells will be required. 
Table – 3.4: In Vitro cytotoxicity assays and theirs principle 
Sr. 
No. 
Category of 
viability assay 
Type of assay Principles Reference 
1. 
Membrane 
integrity assay 
1. Trypan blue dye 
exclusion assay 
2.Fluorescent dyes 
assay 
3. LDH leakage assay 
The determination of 
Membrane integrity 
via dye exclusion 
from live cells 
Riss et al., 2004 
2. 
Functional 
Assay 
1. MTT, XTT assay 
2. Crystal violet/ Acid 
phosphatise (AP) 
assay 
3. Alamar Blue 
oxidationreduction 
assay 
4. Neutral red assay 
5. [3H]-thymidin/ BrdU 
Incorporation 
Examining 
metabolic 
components that are 
necessary for cell 
growth 
Marshall et 
al., 1995 
 
3. Protein assay SRB assay 
Based on 
measurement of total 
protein content. 
Coppeta and 
Rogers, 1998 
4. 
DNA labeling 
Assay Fluorescent conjugates 
Simultaneous cell 
selection and 
viability assay 
Negoescu 
et al., 1998 
5. 
Morphological 
Assay 
Microscopic 
observation 
Determination of 
morphological 
change 
Kerr et al., 
1972 
6. 
Reproductive 
assay Colony formation assay 
Determination of 
growth rate 
Franken et 
al., 2006 
3.4.5.2 Overview on in-vitro cytotoxicity assay used in experiment 
Colorimetric assay are mainly useful in determination of cellular proliferation, 
viability and activation. The need for sensitive, quantitative, reliable and automated 
methods led to the development of standard assays. Such an example is based on the 
capability of the cells to incorporate a radioactively labeled substance ([3H]- 
thymidine), or to release a radioisotope such as [51Cr] after cell lysis. Cell 
proliferation and viability assays are of particular importance for routine applications. 
Tetrazolium salts MTT and XTT are especially useful for assaying the quantification 
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of viable cells. Both, MTT and XTT work by being to a formazan dye only by 
metabolic active cells (Weyermann, 2005). 
MTT assay 
It is a laboratory test and a standard colorimetric assay for measuring cellular growth. 
It can also be used to determine cytotoxicity of potential medicinal agents and other 
toxic materials. This assay is a sensitive, quantitative and reliable colorimetric assay 
that measures viability, proliferation and activation of cells. The assay is based on the 
capacity of mitochondrial dehydrogenase enzymes in living cells to convert the 
yellow water soluble substrate 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 
bromide (MTT) into a dark blue formazan product which is insoluble in water. The 
amount of formazan produced is directly proportional to the cell number in range of 
cell lines. (Cory et al., 1991). 
 
Figure 3.5: Principle of MTT assay 
 Application 
MTT used for the nonradioactive, spectrophotometric quantification of cell 
proliferation and viability in cell populations using the 96-well-plate format. It can be 
used for: 
• Measurement of cell proliferation in response to growth factors, cytokines, 
mitogens, and nutrients. 
• Analysis of cytotoxic and cytostatic compounds, such as anti-cancer drugs and 
other pharmaceutical compounds. 
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• Assessment of growth-inhibitory antibodies and physiological mediators. 
(Wilson, 2000) 
  Advantages of MTT assay 
• Rapid, versatile, quantitative and highly reproducible 
• Adaptable to large-scale screening; relevant for most cells 
• MTT reduction correlates to indices of cellular protein and earlier cell number 
• More sensitive and earlier predictor of toxicity than classical LDH or neutral 
red measurements 
 Disadvantage of MTT assay 
• Production of the MTT product is dependent on the MTT concentration in the 
medium. The kinetics and degree of saturation are dependent on cell type. 
• Assay is less effective in the absence of cell proliferation. 
• MTT cannot distinguish between cytostatic and cytocidal effect. 
• Individual cell numbers are not quantitated and results are expressed as a 
percentage of control absorbance. 
• Test is less effective if cells have been cultured in the same media that has 
supported growth for a few days, which leads to underestimation of control 
and untreated samples (Bernas et al., 2002). 
3.4.6 Abscisic acid and cancer 
Many phytohormones such as jasmonates and salicylates have been shown to 
suppress growth of various types of cancer cells (Flescher and Eliezer, 2005). Limited 
information is available in the peer-reviewed literature regarding the possible role of 
ABA in the prevention and treatment of cancer. A patent was issued to Livingston-
Wheeler in 1976 for its use as an anti-cancer compound (Livingston, 1976). The 
patent describes the use of a solid myeloid leukemia C1498 transplantation model in 
C57BL/6 mice to investigate the anti-cancer efficacy of ABA. The inventor reported 
increased survival rates at 14 days post-transplantation in mice treated with ABA in 
comparison to control mice. The inventor also proposed that ABA “neutralized” the 
human chorionic gonadotropin (hCG) that reportedly coated cancer cells, thereby 
facilitating anti-cancer immune responses ABA may represent a potential cancer 
treatment due to its ability to modulate calcium signalling (Livingston, 1976). 
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Several chemotherapeutic agents modulate pathways leading to increased intracellular 
calcium concentrations. Medications such as staurosporine, doxorubicin, tamoxifen, 
and etoposide act as anti-cancer agents which lead to the death of cancer cells by 
increasing [Ca+2]int resulting in oxidative stress followed by apoptosis (Kruman et al., 
1998; Panaretakis et al., 2005; Parihar et al., 2008). Thus, these pathways activated by 
ABA and those modulated by chemotherapeutic agents used for treating cancer are 
noticeably similar.  
Moreover, epidemiologic studies demonstrated that the consumption of diet rich in 
abscisic acid is associated with a decreased risk of cancer (Riboli and Norat, 2003; 
Wigmore, 1985). Dr. Ann Wigmore mentioned that wheatgrass contains a variety of 
elements that is believed to be anticancer and abscisic acid is one of them. She 
reported that wheatgrass and controlled diet cured breast cancer of few patients. Even 
in experimental animal showed that even a tiny amount of abscisic acid has 
tremendous effect on cancer (Wigmore, 1985). Tan et al. (2006) reported in a China 
patent that ABA effectively inhibits the proliferation of tumour cells; stagnates the 
cells in S phase, stops cell division, and induces differentiation of tumour cells or 
reverts cancerous cells to normal cells. ABA was reported to inhibit proliferation and 
induced differentiation in human SMMC- 7221 cells (Ma et al., 2006) and in nude 
mice transplanted with human hepatocarcinoma (Lu et al., 2007). Additionally, 
abscisic acid is a close relative of Vitamin A. Retinoids (derivatives of Vitamin A) are 
currently used for treatment for breast cancer. Thus, exploring the role of ABA in 
cancer prevention and treatment in the context of well controlled, mechanistically 
oriented projects may result in the development of novel ABA-based 
chemotherapeutic approaches against cancer. 
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3.5 Cacium channel and abscisic acid 
3.5.1 Types: (Rang et al., 2005) 
Table – 3.5: Types and functions of calcium channel 
Gated by Types Characteristics Location / Function Drug effects 
 
Voltage 
      L 
High activation 
threshold, slow 
inactivation 
Plasma membrane of 
many cells; main Ca+ 
source for 
contraction in 
smooth and cardiac 
muscle. 
Blocked by 
dihydropyridines, 
verapamil, diltiazem 
Activated by Bay-K 
8644 
N 
Low activation 
threshold, slow 
inactivation 
Main Ca+ source for 
transmitter release by 
nerve terminals 
Blocked by ω-
conotoxin 
T 
Low activation 
threshold, fast 
inactivation 
Widely distributed; 
important in cardiac 
pacemaker & atria 
( role in 
dysrhythmias) 
Blocked by 
mibefradil 
P/Q 
Low activation 
threshold, slow 
inactivation 
Nerve terminals; 
transmitter release 
Blocked by ω-
agatoxin 
R 
Low activation 
threshold, fast 
inactivation 
- - 
Inositol 
tri- 
Phosphate 
(IP3) 
IP3 
receptor  
Located in ER/SR; 
mediates Ca2+ release 
in response to IP3 
produced by GPCR 
activation 
Not directly targeted 
by drugs; some 
experimental blockers 
known; responds to 
GPCR 
agonist/antagonists in 
many cells 
Ca+2, 
Sensitized 
by 
cADPR 
Ryanodin
e receptor 
Directly activated 
in striated muscle 
via 
dihydropyridine 
receptor of T-
tubules 
Located in ER/SR; 
mediates Ca2+-
evoked Ca2+ release 
in muscle; also 
activated by the 
second messenger 
cADPR 
Activated by caffeine 
(high concentrations), 
blocked by ryanodine 
Store 
depletion 
Store 
operated 
channels 
Indirectly coupled 
to ER/SR Ca+2 
stores 
Located in plasma 
membrane 
Activated indirectly 
by agents that deplete 
intracellular stores 
(e.g. GPCR agonists); 
not directly targeted 
by drugs 
NAADP - Activated by NAADP 
Located in lysosomes 
No clear function   
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3.5.2 Physiological role 
Calcium is the most important regulator of cell function. Many physiological 
mechanisms and drugs operate, directly or indirectly, by influencing the free intra 
cellular concentration of calcium. Different types of Ca+2 channels are involved in 
important physiological functions such as contraction of muscles, activation of 
various enzymes, release of neurotransmitters and hormones, gene transcription, etc. 
Intracellular calcium is usually bound to a protein called calmodulin. The calcium-
calmodulin complex acts together with a further component (RE, response element, 
also a protein) as a protein kinase catalyzing the phosphorylation of numerous 
proteins that themselves control independent but partially parallel developmental 
processes, differentiation, and movements within the cell (Rang et al., 2005). 
Abnormal Ca+2 signalling is involved in many pathophysiological conditions, such as, 
cardiac dysrhythmias, hypertension, epileptogensis, ischaemic cell death, and 
endocrine disorders. 
3.5.3 Drugs acting through Ca+2 channels 
3.5.3.1 Ca+2 channel blockers 
Many clinically important drugs like anti-hypertensive agents (e.g. nifedine, 
verapamil, diltiazem); anti-epileptic drugs (e.g. ethosuximide, sodium valproate, 
gabapentin, pregabalin); antidysrhythmic agents (e.g. class-IV antidysrhythmic 
agents), spasmolytic agents (e.g. dantrolene), etc. act by blocking calcium release 
(Rang et al., 2005). Many other drugs (like G-protein coupled receptor antagonists) 
act indirectly by blocking Ca+2 channels.  
3.5.3.2 Ca+2 channel openers 
Direct Ca+2 channel openers (e.g. Bay-K 8644) are more useful as experimental tool 
rather than as therapeutic agent. Variety of Ca+2 channel openers are useful in 
experimental pharmacology to produce hypertension, arrhythmia, epilepsy, spasm, 
etc. There are many drugs acting indirectly by opening Ca+2 channel like GPCR (G-
protein coupled receptor) agonists, positive inotropic agents (e.g. digoxin), hormones, 
etc. 
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3.5.4 Abscisic acid and Calcium channels 
Over the past few years, evidence from a variety of sources has suggested that 
calcium ions are involved in the molecular events underlying the action of growth 
substance in plants (De Silva et al., 1985). Ca+2 is a second messenger and 
intracellular regulator which regulates of growth and development in plants (Hepler, 
2005). 
Recent studies of the control of stomatal aperture by abscisic acid have suggested that 
its cellular action depends on the availability of calcium ions, which appear to 
function as secondary messengers. In plants, it has been demonstrated that ABA 
stimulates the release of intracellular calcium in conjunction with the up-regulation of 
cyclic ADP-ribose (Wu et al., 1997). In plants, ABA depolarizes plasma membranes, 
which activates potassium ion channels and thereby extrudes K+ outside the cells 
(Schroeder et al., 1987). Ion channel depolarization is dependent on calcium, which is 
an ABA second messenger (Schroeder et al., 2001). The increase in calcium 
concentrations also leads to increased nitric oxide (NO) production (Bodrato et al., 
2009). Huddart et al. (1986) found that ABA may serve as a universal Ca+2 agonist 
across taxonomic kingdoms based on experiments with various smooth muscle 
preparations and a cyanobacterium. 
In contrast, Lynch et al (1991) reported that abscisic acid (ABA) analogue SD217595 
inhibits K+-induced phasic and tonic contractions of rat bladder detrusor smooth 
muscle strips. This dual inhibition was hypothesized due to blockade of two subtypes 
of voltage-operated calcium channels with T- and L-type characteristics. This was 
further supported by finding that ABA is without significant Ca+2 modulatory activity 
in rat prostatic and epididymal vas deferens smooth muscle preparation but the ABA 
analogue SD217595 possesses strong Ca+2 entry blocking ability (Masters et al., 
1994). Thus, role of abscisic acid in relevance to its Ca+2 channel modulatory action is 
controversial. 
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In nutshell the objectives of the present project were: 
 To investigate pharmacological effects of abscisic acid on fructose induced 
insulin resistance 
 
 To screen abscisic acid for in-vitro anti-cancer activity in breast cancer cell-
lines 
 
 To assess Ca+2 channel modulatory action of abscisic acid, using isolated rat 
ileum and in-vivo effect on various cardiac parameters in rat 
 
 To carry out preliminary toxicological study of abscisic acid in rats 
 
 
 
  
 
 
 
 
      
Materials & Methods 
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5.1 Sources of chemicals 
2 – cis, 4 – trans abscisic acid (98%, synthetic) was purchased from Sigma Aldrich, 
USA.   
All the routine reagents, routine chemicals were obtained from Ranbaxy chemicals 
Ltd, Delhi; Qualigens chemicals Ltd, Bombay; S.D. Fine chemicals, Boisar. 
5.2 Experimental models 
5.2.1 Anti-diabetic activity (Fructose-induced insulin resistance in rats) 
5.2.1.1 Indirect type molecular modeling 
3D structural similarity between abscisic acid and thiazolidinedione was checked by 
indirect type of molecular modeling study using PC based Discovery Studio (Version 
2.1, Accelrys Inc. USA). 
5.2.1.2 Animals 
All experiments and protocols described in present study were approved by the 
Institutional Animal Ethics Committee (IAEC) of R. K. College of Pharmacy, Rajkot 
and with permission from Committee for the Purpose of Control and Supervision of 
Experiments on Animals (CPCSEA), Ministry of Social Justice and Empowerment, 
Government of India (Protocol No. RKCP/COL/RP/09/02). 
Ten week old male Sprague-Dawley rats (200 ± 25 gm) were housed in-group of 3 
animal in cages and maintained under standardized condition (12-h light/dark cycle, 
24°C, 35 to 60% humidity) and provided free access to palleted diet and purified 
drinking water ad libitium, unless specified. 
Parameters assessed: 
Serum: Fasting glucose, fasting insulin, fasting insulin 
resistance index (FIRI), oral glucose tolerance test (OGTT), total 
cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, VLDL 
cholesterol. 
Liver:  Glycogen 
Muscle:  Glycogen 
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5.2.1.3 Experimental design 
Rats (n=24) were randomized into following groups: 
1) Normal control (CON): They were administered with vehicle (water) for 30 
days. They were fed with standard laboratory diet and water ad libitum. 
2) Disease control (FRU):- They were administered with vehicle (water) for 30 
days. They were fed with standard laboratory diet and 10% fructose in water 
for 30 days. 
3)  Standard (PIO + FRU):- Pioglitazone (10 mg/kg/day, p.o.) was administered 
for 30 days along with 10% fructose in water. 
4) Test (ABA + FRU):- Abscisic acid (1 mg/kg/day, p.o.) was administered for 
30 days along with 10% fructose in water. 
Rats were weighed and their food/water intake was recorded weekly. On 29th day Oral 
glucose tolerance test was performed. On 30th day animals were used for serum 
collection followed by tissue collection. Serum and tissue were subjected to different 
biochemical analysis. 
5.2.1.4 Oral glucose tolerance test (OGTT) 
Method of Shrwaikar et al. was used for the OGTT. The oral glucose tolerance test 
was performed in overnight fasted rats. Rats divided into four groups (n=6) were 
administered drinking water (normal control and disease control), pioglitazone and 
abscisic acid respectively. Glucose (2g/kg) was fed 30 min after the administration of 
drug. Blood was withdrawn from the retro orbital plexus under light ether anesthesia 
at 30, 60,120 min of glucose administration. 
5.2.1.5 Collection of serum and detection of serum parameters 
The blood samples were withdrawn from retro-orbital plexus under light ether 
anesthesia without any anticoagulant and allowed to clot for 10 minutes at room 
temperature. It was centrifuged at 2500 rpm for 20 minutes. The serum obtained was 
kept at 4ºC until used. 
The serum was estimated for fasting glucose and fasting insulin as described 
following: 
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5.2.1.5.1 Fasting glucose (Teitz NW, 1970) 
In vitro quantitative determination of glucose in serum was done using enzymatic kit 
(ACCUCARE™, Lab – Care Diagnostics India Pvt. Ltd.). 
Principle: 
 Enzymatic colorimetric determination of glucose according to the following 
reactions: 
Glucose Oxidase 
Glucose + O2                                        Gluconic acid + H2O2 
 
                                                                 Peroxidase 
2H2O2 + Phenol + 4-Aminoantipyrine                           Red-violet quinoneimine 
Procedure: 
Pippette in the tubes labeled as follows: 
 Blank Standard Sample 
Sample - - 10 µl 
Standard - 10 µl - 
Reagent 1000 µl 1000 µl 1000 µl 
  
Mix and incubate for 15 min. at 37º C for 30 min. at room temperature. Measure 
absorbance of sample (AT) and standard (AS) against reagent blank at 505 nm. The 
colour is stable for at least 30 min. at room temperature. 
Calculations: 
Fasting Glucose (mg/dl) = 
(𝐴𝐴𝐴𝐴)(𝐴𝐴𝐴𝐴)  x Concentration of standard 
5.2.1.5.2 Fasting insulin 
 Serum fasting insulin was estimated at Saurashtra Pathology Laboratory – 
Rajkot using radio immune assay (RIA) kit. 
Principle: 
 The radioimmunoassay method is based upon the competition of unlabelled 
insulin in the standardized samples and radio iodinated (I-125) insulin for the limited 
binding sites on a specific antibody. 
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 At the end of incubation, the antibody bound and free insulin are separated by 
second antibody-polyethylene glycol (PEG) aided separation method. Insulin 
concentration of samples is quantified by measuring the radioactivity associated with 
the bound fraction of sample and standard. 
5.2.1.5.3 Fasting insulin resistance index (FIRI) (Duncan et al., 1995) 
Fasting insulin resistance index (FIRI) was calculated by following formula 
FIRI= fasting blood glucose in mg/dl x fasting insulin in uU/ml) / 25 
5.2.1.5.4 Estimation of total cholesterol  
(CHOD/POD-Phosphotungstate method) 
In vitro quantitative determination of the activity of cholesterol in serum was done 
using enzymatic kit (Monozyme India Limited). 
Principle: 
Cholesterol esterase (CHE) hydrolyses cholesterol ester. Free cholesterol is oxidized 
by the cholesterol oxidize (CHO) to choloest-4-ene-3-one and hydrogen peroxide. 
Hydrogen peroxide reacts with 4-aminoantipyrine and phenol in the presence of 
peroxidase (POD) to produce pink colored quinoneimine dye. The intensity of color 
produced is proportional to cholesterol concentration. 
Procedure: 
 Pipette into 3 test tubes labeled Blank (B), Standard (S) and Total Cholesterol 
(Tc) as shown below; 
 Blank Standard Total Cholesterol 
Enzyme reagent 1.0 ml 1.0 ml 1.0 ml 
Cholesterol 
standard 
- 20 µl - 
Specimen - - 20 µl 
A) Mix and incubate at 37ºC for 5 minutes (or) RT for 10 minutes. 
Distilled water 2.0 ml 2.0 ml 2.0 ml 
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Read the absorbance of standard, total cholesterol against Blank at 505 nm. 
Calculations: 
Total Cholesterol (mg/dl) = Abs. of Tc / Abs. of S X 200 
5.2.1.5.5 Estimation of triglycerides (GPO Method) 
In vitro quantitative measurement of triglyceride (neutral fat) concentration in serum 
was done by using kit (Reckon diagnostics (India) Pvt. Ltd.). 
Principle: 
Triglycerides in the sample are hydrolyzed by microbial lipase to glycerol and free 
fatty acid (FFA). Glycerol is phosphorylated by adenosine 5-triphosphate (ATP) to 
glycerol 3-phosphate (G-3-P) in reaction catalyzed by glycerol kinase (GK). G-3-P is 
oxidized to dihydroxy acetone phosphate in a reaction catalyzed by the enzyme 
glycerol phosphate oxidase (GPO). In this reaction hydrogen peroxide (H2O2) is 
produced in equimolar concentration to the level of triglycerides present in the 
sample. H2O2 reacts with 4-aminoantipyrine and ADPS in the reaction catalyzed by 
peroxidases (POD). The result of this oxidative coupling is a quinoneimine purple 
colored dye. 
The absorbance of this dye in solution is proportional to the concentration of 
triglycerides in sample. 
Procedure: 
 Blank Standard Test 
Working reagent 1.0 ml 1.0 ml 1.0 ml 
Standard - 20 µl - 
Specimen - - 20 µl 
A) Mix and incubate at 37ºC for 15 minutes. 
Distilled water 1.5 ml 1.5 ml 1.5 ml 
Mix and read the absorbance of test and standard against reagent blank at 546 nm. 
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Calculations: 
Triglycerides (mg/dl) = Abs. of Test/ Abs. of Std.  X   50 
5.2.1.5.6 Estimation of HDL-cholesterol (CHOD/POD-Phosphotungstate method) 
In vitro quantitative determination of the activity of cholesterol in serum was done 
using enzymatic kit (Monozyme India Limited.) 
Principle: 
The VLDL and LDL fractions of serum sample are precipitated using PTA and then 
HDL in the supernatant is separated by centrifugation and measured for its cholesterol 
content. The enzyme cholesterol ester hydrolase (CHE) hydrolyses the ester 
cholesterol. Then cholesterol is oxidized by cholesterol oxidase (CHO) to cholest-4-
en-3-one and hydrogen peroxide. Hydrogen peroxide in presence of enzyme 
peroxidase (POD) reacts with 4-aminoantipyrine and phenol to produce a red colored 
complex, whose absorbance is proportional to HDL-cholesterol concentration. 
Procedure: 
Pipette into a centrifuge tube: 
Serum 0.2 ml 
Precipitating Reagent 0.3 ml 
Mix well and allow standing at RT for 5 minutes. Centrifuge at 3000 rpm for 10 
minutes to get a clear supernatant. If the supernatant is not clear (high TGL level) 
dilute the sample 1:1 with normal saline. Pipette into 3 test tubes labeled Blank (B), 
Standard (S) and HDL Cholesterol (H) as shown below; 
 Blank Standard HDL Cholesterol 
Enzyme reagent 1.0 ml 1.0 ml 1.0 ml 
Cholesterol 
standard 
- 20 µl - 
Supernatant - - 20 µl 
A) Mix and incubate at 37ºC for 5 minutes (or) RT for 10 minutes. 
Distilled water 2.0 ml 2.0 ml 2.0 ml 
Read the absorbance of standard, total cholesterol against Blank at 505 nm. 
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Calculations: 
HDL Cholesterol (mg/dl) = Abs. of H / Abs. of S X 50 
5.2.1.5.7 Estimation of LDL-cholesterol (Tiwari and Gode, 1990) 
Estimation of LDL-cholesterol was done using the Friedewald formula. 
LDL cholesterol = total cholesterol – (HDL cholesterol + VLDL cholesterol) 
5.2.1.5.8 Estimation of VLDL-cholesterol (Tiwari and Gode, 1990) 
Estimation of VLDL-cholesterol was done using the Friedewald formula. 
VLDL cholesterol = triglycerides / 5 
5.2.1.6 Liver and Muscle Glycogen (Stafford et al., 1955) 
The liver and thigh muscle were removed and blotted on filter paper to remove blood, 
weighed, dropped into flasks containing 10 ml hot 30% potassium hydroxide and 
digested on a hot plate. The digest was diluted to 100 ml and a 50-fold dilution of an 
aliquot was used for analysis. Ten ml 0.2% anthrone in 95% sulfuric acid was slowly 
added to 5 ml of liver digest dilution with cooling. The mixture was heated in a 
boiling water bath for 10 min and then placed into cold water. Optical density was 
measured in a spectrophotometer at 620 μm using the anthrone-reagent as blank. 
Calibration curves were established using glucose as standard. 
  
 Materials and Methods  
[66] Devang B. Sheth 
5.2.2 Anti-cancer activity 
5.2.2.1 Indirect type molecular modelling 
3D structural similarity between abscisic acid and vitamin A was checked by indirect 
type of molecular modeling study using PC based Discovery Studio (Version 2.1, 
Accelrys Inc. USA). 
5.2.2.2 Material  
5.2.2.2.1 Reagents  
1. Trypan blue Dye (Hyclone, Lot No: 029K2358, 100 ml)  
2. Triton X100 (MP Biomedicals, Lot No: 8009H, 100 ml)  
3. DMSO cell culture grade (Bioworld, Lot No: 1388B230, 500 ml)  
4. Sodium bicarbonate (Bioworld, Lot No: 1775B29)  
5. Amphotericin B (Himedia, Lot No: 1397893, 100 ml)  
6. Penicillin and Streptomycin solution stabilized (Sigma, Lot No: 1208029, 100 
ml)  
7. EDTA (MP Biomedicals, Lot No: YY02022B207Y)  
8. DPBS modified 1X (Dulbecoo’s phosphate buffer saline without Ca+ and 
Mg+) (Himedia, Lot No: LW537, 100 ml)  
9. Trypsin 1X Gamma irradiated (SAFC Bioscience, Lot No: 8NO535, 500 ml)  
10. Methotrexate (MP Biomedicals, Cat no. 102299, Lot no. R27204)  
11. Triton – X 100 (Bioworld, Cat no. 730208, Lot no. 18278075)  
12. Iso Propanol (Finar Chemicals, Cat no. 11390, Lot no. 19075330)  
5.2.2.2.2 Media 
1. DMEM (Dulbecoos Modified Eagels medium, low glucose with glutamine) 
(MP Biomedical, Lot No: C1478)  
2. FBS (Fetal Bovine Serum, South American origin, 500 ml) (Quaditive, Lot 
No: 103128, 500 ml) 
3. SFM HEKTM (Hyclone, Lot no: ARF26635, 500ml) 
4. Fluid thioglycolate media (TGM) (Himedia, Lot No: YHI25) 
5. Tryptone Soya broth (TSB) (Himedia, Lot No: YH031) 
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5.2.2.2.3 Cell lines 
1. MCF-7 celline (Breast cancer cell line) 
2. MDA-MB-468 (Breast cancer cell line) 
3. HEK293T (Human Embryonic Kidney cell line - Normal cell line) 
5.2.2.2.4 Glass wares and plastic wares  
1. 96-well microtiter plate (Flat Bottom, U Bottom, V Bottom)  
2. Tissue culture flasks (75 cm2 T Flask vented and 150 cm2 T Flask vented) 
3. Falcon tubes (15 ml, 50 ml), Cryotubes (2 ml), Cell scrapper  
4. Micro tips (Blue 1000 μl, Yellow 200 μl, White 10 μl) (Volex) 
5. Reagent bottles (100 ml, 250 ml, 500 ml, 1000 ml) 
6. Haemocytometer cell counting chamber 
5.2.2.2.5 Equipments  
1. Fluorescence inverted microscope (Leica DM IL, Germany) 
2. Biosafety cabinet classII (Esco, Singapore)  
3. Cytotoxic safety cabinet (Esco, Singapore) 
4. CO2 incubator (RS Biotech, mini galaxy A, Scotland)  
5. Deep freezer (Dairei, Denmark) 
6. ELISA plate reader (Thermo, USA) 
7. Micropipettes (Eppendorff, Germany)  
8. RO water system (Millipore, USA) 
9. Electronic water bath (Genei, India) 
5.2.2.2.6 Cell proliferation kit  
1. MTT Dye Powder (Serva Electrophoresis, Cat no. 20395, Lot no. 080364) 
5.2.2.3 Methods  
5.2.2.3.1 Characterization of Cell Lines and Culture Media  
Characterization is essential not only when deriving new lines, but also when a cell 
line is obtained from a cell bank or other laboratory. Cultures were examined under an 
inverted phase microscope before start of experiments and frequent assessments are 
made of the viability of the cell population throughout the experimental periods. 
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5.2.2.3.1.1 Testing for Microbial Contamination  
The two methods generally used by us in our laboratory to check for bacterial and 
fungal contamination. Detection carried out using special media like Fluid 
thiogycolate media (TGM) and Tryptone Soya broth (TSB) and direct observation 
using Grams stain.  
Contamination by bacteria, yeast or fungi was detected by an increase in turbidity of 
the medium and/or a decrease in pH (yellow in media containing phenol red as a pH 
indicator). Cells were inspected daily for presence or absence of microbial growth. 
5.2.2.3.1.2 Protocol (Freshney, 2001)  
• Cell lines were cultured in the absence of antibiotics prior to testing using 25 
cm2 non-vented T-flask.  
• In case of adherent cell line, attached cells were bringing in to into suspension 
using a cell scraper. Suspension cell lines were tested directly.  
• 1.5 ml test sample (cells) were Inoculated in to two separate test tubes of each 
containing Thioglycollate Medium (TGM) and Tryptone Soya broth (TSB).  
• 0.1 ml E. Coli, 0.1 ml B. Subtilis and 0.1 ml C. Sporogenes inoculated in to 
separate test tubes (duplicate) containing (TGM) and (TSB). These were act as 
positive controls where as two separate test tubes of each containing (TGM) 
and (TSB) un-inoculated as negative controls.  
Broths were incubated as follows:  
• For TSB, one broth of each pair were incubated at 32 ºC the other at 22 ºC for 
4 days.  
• For TGM, one broth of each pair were incubated at 32 ºC the other at 22 ºC for 
4 days.  
• For the TGM inoculated with C. Sporogenes incubate at 32 ºC for 4 days.  
Note: Test and Control broths were examined for turbidity after 4 days. 
Criteria for a Validity of results: If control broths show evidence of bacteria and 
fungi within 4 days of incubation in all positive control broths and the negative 
control broths show no evidence of bacteria and fungi. 
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Criteria for a Positive Result: Test broths containing bacteria or fungi show 
turbidity.  
Criteria for a Negative Result: Test broths should be clear and show no evidence of 
turbidity. 
5.2.2.3.2 Preparation of media 
5.2.2.3.2.1 Preparation of DMEM 
13.37 gm of DMEM powder was added in 1litre of distilled water and then it was 
stirred continuously until clear solution formed. To this, NaHCO3 was added to 
maintain pH 7.0 – 7.2 and then solution was filtered using membrane filtration 
assembly. It was sterile in autoclave and stored in reservoir bottle in refrigerator at 
4oC. 
5.2.2.3.2.2 Preparation of the Trypsin dilution 
5 ml of Trypsin solution was pipette out in to 50 ml falcon centrifuge tube containing 
45 ml of PBS using 10 ml pipette. 
5.2.2.3.3 Determination of cell viability, density and population doubling time  
The quantification of cellular growth, including proliferation and viability, has 
become an essential tool for working on cell-based studies.  
5.2.2.3.3.1 Cell viability by Trypan Blue Dye Exclusion Method  
The viability of cells was determined by the Trypan Blue dye exclusion method. It 
takes advantage of the ability of healthy cells with uncompromised cytoplasmic 
membrane integrity to exclude dyes such as trypan blue. (Freshney, 2001) 
5.2.2.3.3.2 Haemocytometer Cell Counts  
1. Hemocytometer and cover slip were cleaned and wiped with 70% alcohol. 
Then cover slip was placed on haemocytometer.  
2. In separate 2 ml centrifuge tube, cell suspension (cells in culture media) was 
added. Then two fold dilution of reaction mixture was prepared by mixing 
aliquot of 0.1 ml cell suspensions with 0.1 ml trypan blue.  
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3. Afterwards 0.1 ml of cell suspension was then placed in to chamber of 
haemocytometer.  
4. By using a Lieca inverted microscope, numbers of cells were counted in 1 
mm2 area with use of 10X objective lens.  
5. Viable and non-viable cells were counted in both halves of the chamber. 
5.2.2.3.3.3 Calculations  
(1) Total number of viable cells = A × B × C × 104  
(2) Total dead cell count = A × B × D × 104  
Where,  
A = Vol. Of cell solution (ml)  
B = Dilution factor in trypan blue  
C = Mean number of unstained cells  
D = Mean number of dead/stained cells  
104 = Conversion of 0.1 mm3 to ml  
(3) Total cell count = Viable cell count + dead cell count 
 % viability = (Viable cell count / Total cell count) × 100  
Note: Cell quantification, module 4B:1, Hemocytometer cell counts and viability 
studies, 1.1 – 1.5 used as reference in counting of cells. 
 Cell density: cells/cm2  
It was particularly important in case of adherent cell line like MCF – 7 and HEK 
293T. It was calculated by following equation:  
[No. of cells / well or flask] / [surface area of well or flask] 
 Population doubling time (PDT)  
It is the time expressed in hours, taken for cell number to double and is reciprocal of 
the multiplication rate (1/r).  
NH = No. of cells harvested at the end of growth period that is t2  
NI = No. of cells inoculated at time t1= 0  
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n = 3.32 (log NH ― log NI)  
PDT = total time elapsed / no. of generations = 1/r 
 Multiplication rate (r): No. of generation that occurs per unit time and is usually 
expressed as population doubling in 24 hours.  
r = 3.32 (logNH ― logNI) / t2 – t1 
5.2.2.4 Preparation of compound dilution 
5.2.2.4.1 Preparation of test Sample  
Test sample was dissolved in DMSO (2%) solution and appropriately diluted using 
same solvent to prepare different concentration of test compound in micro molar 
concentration. 
Note: The final concentration of DMSO (2%) used does not interfere cell viability 
(Li-Jun Yang et al; 2009) 
5.2.2.4.2 Dilution of Test Compound 
100 μl of 1mM concentration of test compound was added in to 900 μl of complete 
media and as a result 100 μM concentration of test sample was obtained.  
Then 1:3 dilution of test sample was done as shown in Table. It was done by mixing 
50 μl of test compound with 100  μl of complete media. For th is, in itially 100  μl of 
complete media was added in to well no. 1 – 9. Well 10 contained 150 μl test 
substance only, from that 50 μl was pipetted out and added into well no. 9 which 
already contain 100 μl of complete media, which lead to 1:3 dilution of test sample. 
Same procedure was repeated 9 times in order to get final conc. of test Sample up to 
0.005 μm (Table 5.1). 
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Table - 5.1: Dilution of test compound used in the assay 
Well no. 1-9 contain complete media 100µl 
Well No. 1 2 3 4 5 6 7 8 9 10 
Compound 
dilution 
50 µl 
mixture 
from 
well 2 
50 µl 
mixture 
from 
well 3 
50 µl 
mixture 
from 
well 4 
50 µl 
mixture 
from 
well 5 
50 µl 
mixture 
from 
well 6 
50 µl 
mixture 
from 
well 7 
50 µl 
mixture 
from 
well 8 
50 µl 
mixture 
from 
well 9 
50 
µl 
T.C. 
from 
well 
10 
150 
µl 
T.C. 
Final con. 
(µM) 0.005 0.015 0.045 0.13 0.41 1.23 3.7 11.1 33.3 100 
 
Where, T.C. = Test compound 
5.2.2.4.3 Reference substance  
Doxorubicin, a cytotoxic substance used in anti-neoplasic therapy, was evaluated in 
the same cellular system to obtain cytotoxicity parameters, allowing us to classify the 
thiazole derivatives according to their relative toxicity. M.W. of Doxorubicin is 545.3 
gm/mol. Stock solution of it was prepared with 1 ml of DMSO, which produces stock 
solution of Doxorubicin of 10 mM concentration. Stock solution was further diluted 
for 10 times using DMSO to obtain 100 μM solution. 
Table - 5.2: Plate assignment 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.005 
μM/ml 
0.01 
μM/ml 
0.04 
μM/ml 
0.13 
μM/ml 
0.41 
μM/ml 
1.23 
μM/ml 
3.7 
μM/ml 
11.11 
μM/ml 
33.33 
μM/ml 
100 
μM/ml NC PC 
B 0.005 
μM/ml 
0.01 
μM/ml 
0.04 
μM/ml 
0.13 
μM/ml 
0.41 
μM/ml 
1.23 
μM/ml 
3.7 
μM/ml 
11.11 
μM/ml 
33.33 
μM/ml 
100 
μM/ml NC PC 
Where, PC = Positive control (cells + media; no drug),  
NC = Negative control (only complete media; no cells; no drug)  
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5.2.2.5.1 Experimental setup 
5.2.2.5.1.1 Cell lines and culture medium 
MCF-7, MDA – MB468 and HEK293T cell cultures derived from National Centre for 
Cell Science (NCCS) - Pune, were used in these experiments. Stock cells of these cell 
lines were cultured in DMEM, supplemented with 10% FBS (fetal bovine serum). 
Along with media cells were also supplemented with 5 % HBSS, penicillin, 
streptomycin and Amphotericin – B, in a humidified atmosphere of 5 % CO2 at 37 °C 
until confluence reached. The cells were dissociated with 0.2 % trypsin, 0.02 % 
EDTA in phosphate buffer saline solution. The stock cultures were grown initially in 
25 cm2 tissue culture flasks, than in 75 cm2 and finally in 150 cm2 tissue culture flask 
and all cytotoxicity experiments were carried out in 96 microtitre well-plates. 2 × 104 
cells/well was added in to each well of 96 well-plates. It was calculated as followed: 
5.2.2.5.1.2 Calculation for number of cells in 96 well plates 
For this we need to calculate for no. of cells required for 100 wells ≈ 96 well,  
No. of cells / well × 100 
= 2 × 104 × 100  
= 2 × 106 cells / plate  
Total volume of media for 100 wells  
= volume of media / well × 100  
= 100 μl × 100  
= 10 ml  
Therefore, we need a total of 2 × 106 cells in 10 ml of medium, then aliquot the 
required volume of cell suspension in to each wells. 
5.2.2.5.1.3 Design of experiment 
Cell lines in exponential growth phase were washed, trypsinized and re-suspended in 
complete culture media. Cells were seeded at 2 × 104 cells / well in 96 well microtitre 
plate and incubated for 24 hrs during which a partial monolayer forms. The cells were 
then exposed to various concentrations of abscisic acid (as indicated in plate 
assignment) and standard doxorubicin. Control wells were received only maintenance 
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medium. The plates were incubated at 37 °C in a humidified incubator with 5% CO2, 
75% relative humidity for a period of 24 hrs. Morphological changes of drug treated 
cells were examined using an inverted microscope at different time intervals and 
compared with the cells serving as control. At the end of 24 hrs, cellular viability was 
determined using MTT assay. 
5.2.2.5.2 Screening of Test Compound by MTT Assay 
5.2.2.5.2.1 Protocol  
• Cells were pre incubated at a concentration of 1 × 106 cells / ml in culture 
medium for 3 hrs at 37°C and 6.5% CO2, 75% relative humidity.  
• Cells were seeded at a concentration of 5 × 104 cells / well in 100 μl culture 
medium and various amounts of compound (final concentration e.g. 100 μM – 
0.005 μM) were added into microplates (tissue culture grade, 96 wells, flat 
bottom).  
• Cell cultures were incubated for 24 hrs at 37 °C and 6.5% CO2.  
• 10 μl MTT labeling mixture was added and incubate for 4 hrs at 37 °C and 
6.5% CO2, 75% relative humidity.  
• 100 μl of solubilization solution was added to each well and incubate for 
overnight.  
• Absorbance of the samples was measured using a microplate (ELISA) reader.  
• The wavelength to measure absorbance of the formazan product is between 
540 and 600 nm according to the filters available for the ELISA reader, used 
(The reference wavelength should be more than 650 nm). 
5.2.2.5.2.2 Data interpretation  
Absorbance values that are lower than the control cells indicate a reduction in the rate 
of cell proliferation. Conversely a higher absorbance rate indicates an increase in cell 
proliferation. Rarely, an increase in proliferation may be offset by cell death; evidence 
of cell death may be inferred from morphological changes. After 24 hrs, the 
cytotoxicity data was evaluated by determining absorbance and calculating the 
correspondent chemical concentrations. Linear regression analysis with 95 % 
confidence limit and R2 were used to define dose-response curves and to compute the 
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concentration of chemical agents needed to reduce absorbance of the formazan by 50 
% (IC50). 
Percentage cell growth inhibition or percentage cytotoxicity was calculated by 
following formula: 
% Viability = (AT – AB) / (AC – AB) × 100 … … … (1) 
Where,  
AT = Absorbance of treated cells (drug)  
AB = Absorbance of blank (only media)  
AC = Absorbance of control (untreated)  
There by,  
% Cytotoxicity = 100 – % cell survival … … … (2) 
 Determination of IC50 Value  
According to the FDA, IC50 represents the concentration of a drug that is required for 
50 % inhibition in-vitro. In our study, IC50 is a concentration of drug at which 50 % of 
cell population die.  
For primary screening, we use a threshold of 50 % cell growth inhibition as a cut off 
for compound toxicity against cell lines. IC50 is determined from plot of Dose 
Response curve between log of compound concentration and percentage growth 
inhibition. IC50 value has been derived using curve fitting methods with Graph Pad 
Prism as stastical software (Ver. 5.02) (Vanicha vichai et al.; 2006). IC50 values were 
calculated using the nonlinear regression program Origin The average of two 
(duplicates manner) were taken in determination. 
Graph was plotted by keeping log concentration of drug on X axis and % cell growth 
inhibition or % cytotoxicity Y axis. IC50 was estimated as a concentration of drug at 
50 % position on Y axis. The relationship should be sigmoidal, log drug concentration 
on the X axis and 'response / measurement' of the Y axis. 
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5.2.3 Ca+2 channel modulatory action 
5.2.3.1 Animals 
All experiments and protocols described in present study were approved by the 
Institutional Animal Ethics Committee (IAEC) of R. K. College of Pharmacy, Rajkot 
and Maliba Pharmacy College, Bardoli with permission from Committee for the 
Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry 
of Social Justice and Empowerment, Government of India (Protocol No. 
RKCP/COL/RP/09/02; MPC 1206). 
5.2.3.2 Effects on isolated rat ileum 
5.2.3.2.1 Material 
5.2.3.2.1.1 Apparatus 
1. Mammalian organ bath 
2. Isotonic frontal writing lever 
3. Recording drum 
4. Aeration tube cum tissue holder 
5. Dissection box 
5.2.3.2.1.2 Chemicals 
1. Tyrode solution 
2. Barium chloride 
3. Papaverine 
5.2.3.2.2 Method (Goyal et al., 2010) 
Healthy Wistar male rats weighing 230-250 gm (n=3) were kept for overnight fasting. 
They were sacrificed as per CPCSEA guidelines. The abdomen was quickly opened 
and a piece of ileum is isolated. It was placed in a petridish containing Tyrode 
solution maintained at 37º C. The mesentry of ileum was removed and the lumen of 
ileum was cleaned by passing warm Tyrode through it from a pipette held at an angle 
of about 20-30 degrees. The tissue was mounted in mammalian organ bath and 
connected to isotonic frontal writing lever. The tissue was allowed to stabilize for 30 
min. The responses for abscisic acid at concentration of 1,10 and 100 µg/ml were 
taken alone and in presence of BaCl2 / papaverine. 
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5.2.3.3 Effect on cardiovascular system parameters 
5.2.3.3.1 Material  
5.2.3.3.1.1 Apparatus 
1. Power Lab 
2. Blood pressure transducer 
3. Pair of scissors  
4. Burette 
5.2.3.3.1.2 Chemicals 
1. Saline 
2. Heparin 
3. Urethane  
4. Verapamil 
5.2.3.3.2 Method (Ordodi et al., 2005) 
Healthy Wistar male rats (230-250 gm) were anesthetized with urethane (1200 
mg/kg). Femoral vein was cannulated with fine polyethylene catheter for 
administration of the drug. Tracheostomy was performed and blood pressure (BP) was 
recorded from left common carotid artery using pressure transducer by direct method 
on Chart data system (Power Lab/4SP, AD Instrument, Australia). Heparinized saline 
(100 IU/ ml) was filled in the transducer and in the fine polyethylene catheter 
cannulated to the carotid artery to prevent clotting. After 30 min of stabilization, mean 
change in blood pressure, heart rate and ECG were recorded for before and after 
administration of abscisic acid (0.1 mg/kg). Effect of abscisic acid was checked in 
presence of verapamil (0.1 mg/kg)/ Calcium gluconate (0.1 mg/kg). 
5.3 Preliminary toxicity testing 
The rats (n=6) were treated with abscisic acid (1 mg/kg/day, p.o.) for 30 consecutive 
days. These rats were observed during the treatment period for over clinical signs of 
toxicity and stress as compared to control (vehicle treated) rats. On 30th day, blood 
was collected by retro-orbital method under light ether anaesthesia. Collected 
uncoagulated blood was used for measurement for total RBC count, white blood cell 
count (total and differential), platelet count and haemoglobin content (Ghai, 2000). 
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The animals (n=4) were then sacrificed. Part of liver, heart, lung (right) and kidney 
(right) tissues were dissected out and kept immediately in 10% formalin for storage. 
Histopathology studies were performed. 
5.4 Statistical analysis 
All the values are expressed as mean S.E.M. Statistical significance between more 
than two groups was tested using one-way ANOVA followed by the Bonferroni 
multiple comparisons test or unpaired two-tailed student's t-test as appropriate using 
computer based fitting program (Prism, Graphpad). Differences were considered to be 
statistically significant when p < 0.05. 
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6.1 Anti-diabetic activity (Fructose-induced insulin resistance in rats) 
6.1.1 Indirect type molecular modelling 
3D structural similarity between abscisic acid and thiazolidinedione was confirmed by 
indirect type of molecular modeling study. Both the structures were generated, energy 
minimized and superimposed (Figure-6.1) using PC based Discovery Studio (Version 
2.1, Accelrys Inc. USA). All geometries were fully optimized by minimizing the 
energy with respect to geometrical variables without symmetry constraints, using a 
0.01 kcal/mol gradient. The r.m.s.d. observed was 0.325. The low root mean square 
distance (r.m.s.d.) value suggests good 3D similarity between abscisic acid and 
thiazolidinedione. 
       
3D structure of thiazolidinedione     3D structure of abscisic acid core 
 
Figure-6.1: 3D Overlay of abscisic acid (green) and thiazolidinedione (pink) 
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6.1.2 Oral glucose tolerance test (OGTT) 
Oral glucose tolerance test (OGTT) showed that at all time intervals fructose 
treatment significantly (p<0.01) increased the serum glucose levels as compared to 
normal group. Abscisic acid as well as pioglitazone treatment significantly (p<0.01) 
decreased the fasting serum glucose levels as compared to fructose treated animals 
(Table-6.1, Fig-6.2). 
Table-6.1: Effect of Abscisic acid (1 mg/kg/day, 30 days) on oral glucose tolerance 
test (OGTT) in fructose-induced insulin resistance in rats 
  
Figure-6.2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on oral glucose tolerance 
test (OGTT) in fructose-induced insulin resistance in rats 
All values represents Mean ± SEM; n=6 
**   Significantly different from normal control (p < 0.01) 
##  Significantly different from disease control (p < 0.01)  
Treatment 
(n=6) 
Time (minutes) 
0 30 60 120 
Normal control 
(CON) 77 ± 1.23 105 ± 3.45 134 ± 4.33 86 ± 7.21 
Disease control 
(FRU) 115 ± 4.55
** 224 ± 8.64** 276 ± 9.23** 198 ±10.76** 
Standard (PIO + 
FRU) 80 ± 0.54
## 115 ± 2.53## 112 ±6.27## 90 ± 7.63## 
Test (ABA + 
FRU) 82 ± 0.98
## 125 ± 4.33## 119 ±5.22## 95 ± 5.74## 
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6.1.3 Serum parameters 
Serum parameters were found to be increasing significantly with administration of 
10% fructose feeding for 30 days. Fructose significantly increased serum fasting 
glucose (p<0.01), serum insulin (p<0.05) and FIRI (p<0.01) as compared to control 
group (n=6). 
Pioglitazone and abscisic acid both exhibited significantly reduction in serum fasting 
glucose as compared to disease control. Treatment with abscisic acid (1 mg/kg, p.o.) 
and pioglitazone (10 mg/kg, p.o.) for 30 days in fructose fed rats resulted in serum 
fasting glucose, 82 ± 0.98 and 80 ± 0.54 mg/dl,  respectively as compared to 115 ± 
4.55 mg/dl in disease control (Table-6.2, Fig-6.3). Abscisic acid showed significant 
anti-hyperglycaemic activity by bringing back serum fasting glucose near to normal 
as identical to pioglitazone.  
Both abscisic acid (1mg/kg) and pioglitazone (10mg/kg) treatment resulted in 
significant decrease (p<0.05) in fasting insulin, 24 ± 0.26 and 23 ± 0.42 µU/ml,  
respectively as compared to 29 ± 0.15 µU/ml in disease control (Table-6.2, Fig-6.4). 
Fasting insulin resistance index (p<0.01) was also found to be reduced as compared to 
disease control group (Table-6.1, Fig-6.5), indicating improvement in insulin 
resistance produced by fructose feeding. 
Table-6.2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting glucose, 
serum fasting insulin and fasting insulin resistance index in fructose-induced insulin 
resistance in rats 
 
Treatment 
(n=6) 
Serum fasting 
glucose (mg/dl) 
Serum fasting 
insulin (µU/ml) 
Fasting insulin 
resistance index 
(FIRI) 
Normal control 
(CON) 77 ± 1.23 22 ± 0.38 67.76 
Disease control 
(FRU) 115 ± 4.55 
** 29 ± 0.15 * 133.4 **  
Standard (PIO + 
FRU) 80 ± 0.54 
## 23 ± 0.42  # 73.6 ## 
Test (ABA + 
FRU) 82 ± 0.98 
## 24 ± 0.26  # 78.72 ## 
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Figure-6.3: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting glucose 
in fructose-induced insulin resistance in rats 
All values represents Mean ± SEM; n=6 
**    Significantly different from normal control (p < 0.01) 
##   Significantly different from disease control (p < 0.01) 
 
Figure-6.4: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting insulin in 
fructose-induced insulin resistance in rats 
All values represents Mean ± SEM; n=6 
*   Significantly different from normal control (p < 0.05) 
#  Significantly different from disease control (p < 0.05)  
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Figure-6.5: Effect of Abscisic acid (1 mg/kg/day, 30 days) on fasting insulin 
resistance index in fructose-induced insulin resistance in rats 
 
Figure-6.6: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum lipid profile 
parameters in fructose-induced insulin resistance in rats 
All values represents Mean ± SEM; n=6 
*    Significantly different from normal control (p < 0.05) 
#   Significantly different from disease control (p < 0.05) 
**   Significantly different from normal control (p < 0.01) 
##  Significantly different from disease control (p < 0.01) 
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Fructose feeding significantly decreased serum HDL (p<0.01) and increased serum 
total cholesterol (p<0.01), serum triglycerides (p<0.01), serum LDL (p<0.01) and 
serum VLDL (p<0.01) as compared to control group (n=6).  Both abscisic acid 
(1mg/kg) and pioglitazone (10mg/kg) treatment resulted in significant increase 
(p<0.05) in serum HDL as compared to disease control (Table-6.3, Fig-6.6). Both 
abscisic acid (1mg/kg) and pioglitazone (10mg/kg) treatment decreased the rise in 
total serum cholesterol (p<0.01), serum triglycerides (p<0.01), serum LDL (p<0.01) 
and serum VLDL (p<0.05) observed with fructose feeding significantly. Although 
abscisic acid (1mg/kg) and pioglitazone (10mg/kg) treatment both decreased lipid 
abnormalities significantly, the effect of abscisic acid was apparently more on serum 
triglycerides as compared to pioglitazone treatment (Table-6.3, Fig-6.6). 
Table-6.3: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum lipid profile 
parameters in fructose-induced insulin resistance in rats 
6.1.4 Liver and muscle glycogen 
Liver and muscle glycogen stores were found to be decreasing (p<0.01 and p<0.05 
respectively) with fructose supplement, as compared to control group, indicating 
development of insulin resistance. Both abscisic acid (1mg/kg) and pioglitazone 
(10mg/kg) treatment increased liver and muscle glycogen stores significantly (p<0.01 
and p<0.05 respectively), as compared to disease control, showing considerable 
increase in insulin sensitivity (Table-6.4, Fig-6.7 and 6.8). 
Lipid profile 
parameters 
(mg/dl) 
Treatment (n=6) 
Normal 
control (CON) 
Disease 
control (FRU) 
Standard 
(PIO+FRU) 
Test 
(ABA+FRU) 
Serum Total 
Cholesterol 81 ± 4.36 122 ± 11.23
** 92 ± 7.76## 103 ± 8.32## 
Serum 
Triglycerides 44 ± 3.44 106 ± 2.43
** 80 ± 4.76## 63 ± 2.14## 
Serum HDL 51 ± 2.11 32 ± 2.54** 43 ± 3.12# 40 ± 2.87# 
Serum LDL 24 ± 2.54 62 ± 2.14** 38 ± 3.56## 36 ± 1.53## 
Serum VLDL 9 ± 1.43 22 ± 2.13** 15 ± 1.13# 14 ± 1.66# 
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Table-6.4: Effect of Abscisic acid (1 mg/kg/day, 30 days) on liver and muscle 
glycogen in fructose-induced insulin resistance in rats 
 
 
Figure-6.7: Effect of Abscisic acid (1 mg/kg/day, 30 days) on liver glycogen in 
fructose-induced insulin resistance in rats 
 
Figure-6.8: Effect of Abscisic acid (1 mg/kg/day, 30 days) on muscle glycogen in 
fructose-induced insulin resistance in rats  
Treatment 
(n=6) 
Liver glycogen 
(µg/mg of tissue) 
Muscle glycogen 
(µg/mg of tissue) 
Normal control (CON) 24.3 ± 2.3 6.2 ± 0.35 
Disease control (FRU) 17.1 ± 1.74 ** 5.15 ± 0.78 * 
Standard (PIO + FRU) 22.35 ± 0.65 ## 5.95 ± 0.4 # 
Test (ABA + FRU) 22 ± 1.95 ## 6.12 ± 0.89 # 
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6.2 Anti-cancer activity 
6.2.1 Indirect type molecular modelling 
3D structural similarity between Vitamin A and Abscisic acid was confirmed by 
indirect type of molecular modeling study. Both the structures were generated, energy 
minimized and superimposed (Figure-6.9) using PC based Discovery Studio (Version 
2.1, Accelrys Inc. USA). All geometries were fully optimized by minimizing the 
energy with respect to geometrical variables without symmetry constraints, using a 
0.01 kcal/mol gradient. The r.m.s.d. observed was 0.219. The low r.m.s.d. value 
suggests good 3D similarity between Vitamin A and Abscisic acid. 
      
3D structure of abscisic acid          3D structure of vitamin A 
 
Figure-6.9: 3D Overlay of abscisic acid (green) and vitamin A (pink)  
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6.2.2 Characterization of cell lines and culture media 
Characterization of cell lines was performed for detection of microbial and cross 
contamination. Cell lines used in our experiments were free from any kind of 
microbial or fungal contamination (Table-6.5), which in essential in order to continue 
our screening experiments. 
Table-6.5: Results for characterization of cell lines 
Cell line 
% Viability PDT 
(hrs) 
Microbial 
contamination 
Cross 
contamination pH 
Stock After 
MCF – 7 64.46 87.20 23.4 
No 
contamination 
No 
contamination 
7.0 
MDA-
MB-468 
78.34 89.89 28.3 
No 
contamination 
No 
contamination 
7.0 
HEK 
293T 
60.46 87.20 19.3 
No 
contamination 
No 
contamination 
7.5 
From viability studies and Population doubling time (PDT), we have concluded that 
the cell lines derived from NCCS, Pune were initially free from cross contamination. 
6.2.3 Cell viability, density and population doubling time 
The quantification of cellular growth, including proliferation and viability, has 
become an essential tool for working on cell-based studies. 
HEK 293T 
At the time of subculture, density of HEK 293T cell line derived from NCCS, Pune 
was around 1.8 × 107 cells / flask and viability was 61.81 %, which was not suitable 
for cytotoxicity study, considering requirement of cell viability greater than 90 %. In 
order to increase the viability and cell density of HEK 293T cell line, sub-culturing 
was done by using complete media and additional 5 % FBS. As a result, on the fourth 
day morning cell density was increased up to 6.4 × 107 and viability was around 87.98 
% which was suitable for cytotoxicity screening. PDT (Population Doubling Time) 
for HEK 293T was 19.3 hrs. Table-6.6 represents results for subculture of HEK 293T 
cell.  
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Table-6.6: Results for sub-culturing of HEK 293T cell line 
Day 1st 2nd 3rd 4th 
Viable cell count 34 43 70 77 
Non-viable cell count 21 18 17 11 
% Viability 61.81 70.79 80.16 87.98 
Cells/ml 3.6 x 105 5.4 x 105 9 x 105 12.8 x 105 
Total cells in flask (50 ml) 1.8 x 107 2.7 x 107 4.5 x 107 6.4 x 107 
Viable cells in flask (50 ml) 9.81 x 106 16.95 x 106 30.2 x 106 46 x 106 
pH 7.5 5.0 4.5 5.0 
PDT 19.3 hrs 
Average PDT for HEK 293T was found to be 19.3 hrs. As the population of cells in 
the flask increase, more amounts of media were consumed by cells for growth 
purpose and this lead to acidic pH of the media, which requires continuous addition of 
media for maintenance of pH and nutritional requirements. Subculturing was 
performed every 3rd or 4th day i.e. twice in week. 
MCF-7 cell line 
Table-6.7: Results for sub-culturing of MCF-7 cell line 
Day 1st 2nd 3rd 
Viable cell count 27 68 77 
Non-viable cell count 18 27 11 
% Viability 60.46 71.40 87.20 
Cells/ml 3.4 x 105 10.2 x 105 30.2 x 105 
Total cells in flask (50 ml) 1.7 x 107 5.1 x 107 15.1 x 107 
Viable cells in flask (50 ml) 10.7 x 106 38 x 106 139 x 106 
pH 7.5 7.5 7 
PDT 23.4 hrs 
MCF-7 is adherent cell line, viability of which was around 60.46 % and seeded 
density was around 1.7 × 107, which was equivalent to HEK 293T viability but still 
requires passaging for cytotoxicity screening. 
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On subculture, after 48 hrs that on 3rd day morning, viability was increased up to 87.2 
% and cell density was 15.1 × 107 which was found to be suitable to carry out 
experiments. PDT was around 23.4 hrs, so sub culturing was carried out three times in 
week for MCF-7 cell line. Table-6.7 represents result for sub-culturing of MCF-7 cell 
line. 
MDA-MB-468 
In case of MDA-MB-468 cell line, seeded density was around 1.7×107 and viability 
was 62.96% which was higher than HEK 293T viability but still requires passaging 
for cytotoxicity screening. 
Table-6.8: Results for sub-culturing of MDA-MB-468 cell line 
Day 1st 2nd 3rd 
Viable cell count 27 68 164 
Non-viable cell count 17 51 151 
% Viability 62.96 72 92.07 
Cells/ml 3.4 x 105 10.2 x 105 30.2 x 105 
Total cells in flask (50 ml) 1.7 x 107 5.1 x 107 15.1 x 107 
Viable cells in flask (50 ml) 10.7 x 106 38 x 106 139 x 106 
pH 7.5 7.5 7 
PDT 28.3 hrs 
On subculture, after 48 hrs that on 3rd day morning, viability was increased up to 
92.07% and cell density was 15.1×107 which were quite good to carried out 
experiments. PDT was around 28.3 hr. So sub-culturing was carried out three times in 
week for MDA-MB-468 cell line. Table-6.8 represents result for sub-culturing of 
MDA-MB-468 cell line.  
6.2.4 Screening by MTT assay 
All the compounds were evaluated in vitro against panel of three cell lines consisting 
of HEK 293T (Human Embryonic Kidney cell line - Normal cell line), MCF – 7 
(Human breast cancer cell line) and MDA-MB-468 (Human breast cancer cell line) 
cell lines by MTT assay. Results for each test samples were reported as the percent of 
growth inhibition (IC50). For both abscisic acid and doxorubicin, Dose Response 
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Curve (DRC) against both cell line was plotted with 10 analysis point i.e. with 10 
different drug concentrations (Figure 6.10 and 6.11). The concentration causing 50% 
cell growth inhibition (IC50) was determined from DRC using GraphPad Prism 
software (V-5.02). 
Table-6.9: IC50 value (µM) of abscisic acid and doxorubicin against 
breast cancer cell lines by MTT assay 
Drug MCF-7 MDA-MB468 HEK 293T (Normal cell line) 
Abscisic acid 48.39 38.52 ˃100 
Doxorubicin 20.23 23.56 ˃100 
Results as mentioned in Table 6.9 indicate abscisic acid show IC50 value below 
100μM against both MCF-7 cell line and MDA-MB-468. Doxorubicin shown 
comparable IC50 values against both cancer cell lines where as in case of HEK 293T 
(as normal cell line), doxorubicin was found to be inactive, which confirm the 
cytotoxicity of doxorubicin against cancer cell line and inactiveness against 
HEK293T cell line. IC50 value of abscisic acid for MDA-MB-468 was found to be 
38.42 µM, which is comparable with standard IC50 value i.e.23.56 µM. Similarly for 
MCF-7 cell line IC50 value was found to be 48.39 µM, which is also comparable with 
standard doxorubicin IC50 value 20.23 µM. Abscisic acid does not produce cytotoxic 
effect significantly with HEK 293T (i.e. normal cell line-Human Embryonic Kidney 
cell line) with IC50 value ˃ 100 µM  suggesting inactiveness against HEK293T cell 
line. 
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Figure-6.10 (a): DRC of doxorubicin by MTT assay (MCF-7) 
Figure-6.10 (b): DRC of doxorubicin by MTT assay (MDA-MB468) 
 
 
Figure-6.11 (a): DRC of abscisic acid by MTT assay (MCF-7) 
Figure-6.11 (b): DRC of abscisic acid by MTT assay (MDA-MB468) 
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6.4 Ca+2 channel modulatory action 
6.4.1 Effects on isolated rat ileum 
Abscisic acid did not produce any effect in isolated rat ileum at concentration of 1, 10 
and 100 µg/ml. ABA also had no effect on contractile response produced by 1% 
BaCl2, indicating that ABA is without significant Ca+2 modulatory activity in this 
smooth muscle preparation (Table-6.10). 
Table-6.10: Effect of abscisic acid (alone and in presence of 1% BaCl2) on isolated 
rat ileum preparation 
Drug Dose Concentration Height (in mm) 
Abscisic acid (ABA) 0.1ml 1 µg/ml - 
 0.5 ml 1 µg/ml - 
 0.1ml 10 µg/ml - 
 0.5 ml 10 µg/ml - 
 0.1ml 100 µg/ml - 
 0.5 ml 100 µg/ml - 
BaCl2 0.1 ml 1% 22 
ABA + BaCl2(0.1 ml, 1%) 0.1 ml 1 µg/ml 20 
 0.5 ml 1 µg/ml 21 
 0.1ml 10 µg/ml 20 
 0.5 ml 10 µg/ml 19 
 0.1ml 100 µg/ml 19 
 0.5 ml 100 µg/ml 20 
6.4.2 Effect on cardiovascular system parameters 
Abscisic acid produced negligible increase in heart rate in anaesthetized rat (n=6). 
Normal values before administration of ABA (0.1 ml, 0.1 mg/kg) showed 318 ± 3.54 
beats/min and after administration of ABA resulted in 326.67 ± 3.99 beats/min. ABA 
administration resulted in slight increase in systolic (135.83 ± 3.57) and diastolic 
(89.67 ± 1.68) blood pressure as compare to normal systolic (128.67 ± 2.89) and 
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diastolic (88.33 ± 1.86) blood pressure, which was found to be statistically 
insignificant. These effects of abscisic acid were blocked by, Ca+2 channel blocker, 
verapamil (Table-6.11). ECG data were found to be normal after administration of 
ABA. 
Table-6.11: Effect of abscisic acid (0.1 mg/kg, i.v.) and verapamil (0.1 mg/kg, i.v.) 
on heart rate and blood pressure 
Parameter Heart rate (beats/min) 
Blood pressure (mmHg) 
Systolic Diastolic 
Normal 318 ± 3.54 128.67 ± 2.89 88.33 ± 1.86 
Abscisic acid 326.67 ± 3.99 133.83 ± 3.57 89.67 ± 1.68 
Verapamil + Abscisic acid 319.25 ± 4.63 127.98 ± 0.29 87.2 ± 1.26 
All values represents Mean ± SEM; n=6 
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6.5 Preliminary toxicity testing 
Treatment with abscisic acid (1 mg/kg/day, p.o.) for 30 consecutive days resulted in 
no changes in weight in rat. Further there were no signs of toxicity indicated as 
abnormal changes in histopathology of heart, lung (right) and kidney (right) tissues of 
rat (n=4). Hematological data (n=6) revealed increase in total RBC count, Hb content 
and total WBC count which was found to be statistically insignificant (Table-6.12). 
Table-6.12: Effect of abscisic acid (1 mg/kg/day, p.o., 30 days) on weight and 
hematological parameters in rats (n=6) 
Parameter Control ABA treated 
Weight (gm) 249.75 ± 2.5   251.25 ± 4.15 
RBC (x 106/cmm) 7.4 ± 0.23 7.6 ± 0.88 
Hb (g/dl) 13 ± 0.29 13.2 ± 0.26 
WBC (x 103/cmm) 8.3 ± 0.15 8.67 ± 0.43 
Neutrophils (%) 15 ± 0.42 14 ± 0.32 
Lymphocytes (%) 76 ± 0.65 77 ± 0.24 
Eiosinophils (%) 5 ± 0.22 4 ± 0.17 
Monocytes (%) 3 ± 0.46 4 ± 0.41 
Basophils (%) 1 ± 0.25 1 ± 0.25 
Platelets (x 105/cmm) 6.5 ± 0.76 6.47 ± 0.82 
All values represents Mean ± SEM; n=6 
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Recent studies on some phytohormones, both in-vivo and in-vitro, have opened new 
avenues to discovery of new chemical entities, in the field of phyto-pharmacology. 
Abscisic acid (ABA) is an important phytohormone that regulates plant growth, 
development, dormancy and stress responses. Recently, it has been discovered that 
ABA is produced by a wide range of animals including sponges (Axinella 
polypoides), hydroids (Eudendrium racemosum), human parasites (Toxoplasma 
gondii) and various mammalian cells (leukocytes, pancreatic cells, and mesenchymal 
stem cells). Since its discovery in early 1960’s, abscisic acid (ABA) has received 
considerable attention as an important phytohormone, and more recently, as a 
therapeutic candidate. Hence, in the present project we attempted to explore 
pharmacological profile of abscisic acid which, on further investigations, could lead 
to discovery of its therapeutic potential. 
In recent decades the prevalence of insulin resistance and type II diabetes has seen a 
precipitous growth (Center for Disease Control and Prevention, 2005). In our study 
abscisic acid was found to be structurally similar to thiazolidinedione as indicated by 
low root mean square distance (r.m.s.d.) in indirect molecular modeling. After 
confirmation of structural similarity, abscisic acid was screened for anti-diabetic 
activity, induced by fructose feeding in rat. 
Fructose feeding for 30 days resulted in hyperglycaemia, hyperinsulinaemia, 
dyslipidemia (decreased levels of HDL and increased levels of LDL, VLDL, total 
cholesterol and triglycerides) and decreased peripheral uptake of glucose. The 
resultant increase in fasting insulin resistance index (FIRI) is also indicative of 
aggravation of insulin resistance. Earlier fructose was considered as a glucose 
alternative in diabetic patients. But later on it was revealed that chronic use of 
fructose culminates in development of metabolic syndrome, including induction of 
insulin resistance. Research in metabolism of fructose has unmasked difference 
between short-term positive effects, and the negative effects of chronic use of 
fructose. Long-term derogatory effects include changes in digestion, absorption, 
plasma hormone levels, appetite, and hepatic metabolism, leading to precipitation of 
insulin resistance, diabetes, obesity, and inevitably cardiovascular disease (Moyer and 
Rodin, 1993).  
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Fructose is a potent regulator of glycogen synthesis and liver glucose uptake. 
Therefore any catalytic improvements are due to hepatic glucokinase and glucose 
uptake facilitation. However, as mentioned, the beneficial effects do not continue with 
chronic fructose utilization. Because of its lipogenic properties, excess fructose in the 
diet can cause glucose and fructose malabsorption, and greater elevations in 
triglycerides and cholesterol compared to other carbohydrates (Hallfrisch J, 1990). Of 
the key importance is the ability of fructose to bypass the main regulatory step of 
glycolysis, the conversion of gluctose-6-phosphate to fructose 1,6-bisphosphate, 
controlled by phosphofructokinase. Thus, while glucose metabolism is negatively 
regulated by phosphofructokinase, fructose can continuously enter the glycolytic 
pathway. Therefore, fructose can uncontrollably produce glucose, glycogen, lactate, 
and pyruvate, providing both the glycerol and acyl portions of acyl-glycerol 
molecules. These particular substrates, and resultant excess energy flux due to 
unregulated fructose metabolism, will promote the overproduction of TG (Mayes, 
1993). It has been further reported that fructose causes metabolic syndrome mediated 
through leptin, adiponectin, and free fatty acids (Heather et al., 2005). 
Pioglitazone as previously reported has been shown to prevent the rise in serum 
biochemical parameters leading to normal levels of glucose, insulin and lipid profile. 
TZDs serve as synthetic ligands for a key metabolic regulator and transcription factor 
known as peroxisome proliferator-activated receptor γ (PPAR γ) (Lehmann et al., 
1995). Following ligand binding, PPAR-γ heterodimerizes with retinoid X receptor 
(RXR), another member of the nuclear receptor superfamily, and subsequently binds 
to a PPAR response element (PPRE) on DNA that initiates the transcription of 
responsive genes. With regard to insulin sensitizers, TZDs appear to be more effective 
in improving glycemic control, controlling metabolic dyslipidaemia and in enhancing 
insulin sensitivity (Seufert et al., 2004; Knowler et al., 2005). 
In our study, abscisic acid treatment for 30 days largely prevented the abnormalities 
produced by fructose feeding. Decrease in insulin resistance was observed to mimic 
pioglitazone treatment. Abscisic acid (ABA) was found to be decrease insulin 
resistance induced by fructose feeding. ABA decreased serum fasting glucose, 
significantly. This is in agreement with previously reported study involving use of 
dietary abscisic acid ameliorating glucose tolerance and obesity-related inflammation 
in db/db mice fed with high-fat diets (Guri et al., 2007). Abscisic acid not only 
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decreased rise in serum fasting glucose and insulin (observed with fructose feeding) 
but also promoted levels of liver and muscle glycogen contents. Thus, abscisic acid 
decreases blood sugar level, reduces over-burdening of pancreatic β-cells (by 
decreasing supernormal serum insulin) and increases uptake of glucose in peripheral 
tissues like liver and muscle. This is clearly indicative of insulin sensitizing action, 
probably via PPAR-γ receptor action. The similarities in structure of ABA and TZDs 
by indirect molecular modeling software studies are also suggestive of PPAR-γ 
receptor agonistic action. Hence, our result confirms previous report indicating 
activation of PPAR-γ responsive genes by abscisic acid in 3T3-L1 pre-adipocytes in 
vitro (Guri et al., 2007). 
Generally, type 2 diabetes mellitus (T2DM) patients suffer from both hyperglycemia 
and dyslipidemia. The insulin resistant state is commonly associated with lipoprotein 
abnormalities that are risk factors for atherosclerosis, including hypertriglyceridemia, 
high levels of very low density lipoprotein (VLDL), low levels of high-density 
lipoprotein cholesterol (Ruotolo G and Howard, 2002), and small, dense LDL 
(Friedlandre et al., 2000). Clinical studies implicate hyperglycemia in the onset of 
microangiopathic complications of T2DM, including kidney failure, retinopathy and 
peripheral neuropathy. However, the major cause of mortality in T2DM patients is 
atherosclerotic macrovascular disease, which culminates in myocardial infarction. 
Such cardiovascular disease appears to result, in large part, from diabetic 
dyslipidemia (Koyama, 2004). 
Many of the genes induced by PPAR-γ, such as aP2 and CD36, are important in fatty 
acid transport, adipogenesis and lipid uptake. Studies have shown that PPAR-γ is an 
essential participant in the differentiation of pre-adipocytes into adipocytes, 
particularly in the subcutaneous adipose tissue depots. This function has been 
proposed to enhance systemic insulin sensitivity by inhibiting lipid efflux from 
adipose tissue into tissues such as the liver, pancreas, skeletal muscle, which are 
important for the proper regulation of glucose homeostasis (Guri et al., 2006; de 
Ferranti et al., 2008). Synthetic PPAR-γ agonists, such as thiazolidinediones (TZDs), 
have been shown to be very effective in improving insulin sensitivity as well as lipid 
dyslipidaemia (Braissant et al., 1996). Present study confirms effect of pioglitazone 
on reducing dyslipidaemia through PPAR-γ activation. Similar pattern of results have 
been observed with ABA treatment in our study. Although both pioglitazone and 
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ABA decreased TG, LDL, and total cholesterol significantly; effect of ABA was 
remarkably better on levels of TG as compared to pioglitazone. Increased delivery of 
triglycerides or non-esterified fatty acids to the muscle interferes with the utilization 
of glucose, through the principles of Randle cycle (Randle, 1998), impairing the 
insulin action. However, in present study we were not been able to co-relate 
hypetriglyceridaemia with hyperinsulinaemia as suggested by FIRI, which was found 
to be same with ABA and pioglitazone treatment. Present study also supports earlier 
finding that ABA-supplementation was associated with significant improvements in 
hepatic steatosis and plasma triglyceride levels (Guri et al., 2008). Further, as reported 
earlier (Guri et al., 2007) we found that ABA treatment is not associated with 
hepatotoxicity and weight gain suggesting substantial safety as compared to TZDs. 
Our results indicate that administration of abscisic acid may be beneficial for 
preservation of functional efficiency of pancreatic β-cells, probably by improving 
insulin action and thereby preventing induction of insulin resistance. The putative 
action of ABA on PPAR-γ receptors is most probable mechanism for its therapeutic 
effect on insulin resistance. Further studies are warranted to establish safety and 
efficacy of abscisic acid in management of diabetes mellitus. 
Deaths from cancer worldwide are projected to continue rising, with an estimated 12 
million deaths in 2030 (WHO, 2011). Breast cancer is the most common cancer 
disease in woman globally. In our study abscisic acid was found to be structurally 
similar to vitamin A as indicated by low r.m.s.d. in indirect molecular modeling. After 
confirmation of structural similarity, abscisic acid was screened for in-vitro anti-
cancer activity in breast cancer cell-lines. 
In the present study, doxorubicin exhibited comparable IC50 values against both 
cancer cell-lines, where as in HEK 293T (i.e. Normal cell line - Human Embryonic 
Kidney cell line), doxorubicin was inactive, confirming cytotoxicity of doxorubicin 
against cancer cell-line and inactivity against HEK293T cell-line. Abscisic acid has 
significant cytotoxicity activity against cell line studied. IC50 value of abscisic acid for 
MDA-MB 468 and MCF-7 cell-line is comparable with std. IC50 value of 
doxorubicin. Further, abscisic acid did not produce cytotoxic effect with HEK293T 
cell-line. 
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Over 60% of breast cancer cases are estrogen receptor (ER) positive, which is highly 
dependent on estrogen for growth. The usage of MCF-7 breast cancer cells lines is 
widely used nowadays in numerous researches for the anti-cancer properties. MCF-7 
cells are the most commonly used model of estrogen positive breast cancer (Soule et 
al., 1973). On other hand, MDA-MB 468 cell-line is ER negative breast cancer cell-
line. Therefore, in this study we assessed effect of abscisic acid on both ER positive 
(i.e. MCF-7) as well as ER negative (i.e. MDA-MB 468) cell-lines. 
Retinoids (derivatives of vitamin A) are signalling molecules that play important roles 
in cell growth, differentiation and death. Retinoids inhibit growth of breast cancer 
cell-lines in culture and inhibit breast tumor growth in animal models as well as 
humans. Therefore we hypothesized to have same observation with abscisic acid. 
Retinoid signals are mediated through the retinoic acid receptors (RARs) and the 
retinoid X receptors (RXRs), with each family represented by three distinct receptor 
genes designated α, β, and γ – which themselves act as ligand-dependent transcription 
factors (Pfahl, 1994; Mangelsdorf and Evans, 1995; Chambon, 1996). They have been 
used successfully to cure acute promyelocytic leukaemia (APL) and can suppress 
carcinogenesis in a variety of tissue types (e.g. breast, skin, lung and oral cancers) 
(Mangelsdorf et al., 1996). Following stimulation by retinoids, RAR-RXR 
heterodimers and RXR-RXR homodimers can form. The receptor dimers bind to 
retinoic acid response elements or retinoid X response elements in the promoter 
sequences of target genes, and they modulate gene transcription. Inhibition of breast 
tumor cell growth by retinoids is greater for ER-positive cells than ER-negative cells 
(Simeone and Tari, 2004). We observed that abscisic acid exerts cytotoxic action for 
both ER positive (MCF-7) as well as ER negative (MDA-MB 468) breast cancer cell-
line indicating that it is not acting through RAR and/or RXR signalling mechanisms. 
Thus, anti-cancer activity of abscisic acid may not be connected with estrogen 
receptor expression. Further, earlier reports have proposed that ABA “neutralizes” the 
human chorionic gonadotropin (hCG), which is a negatively charged glycoprotein that 
reportedly coats cancer cells and prevents immune cells (the outer membranes are 
normally negatively charged) from getting close and attack the cancer cells 
(Livingston, 1976). Thus, abscisic acid may be facilitating anticancer immune 
responses. 
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Cytotoxic effects of ABA could also be due to its ability to modulate calcium 
signalling. ABA modulates pathways in plants and animals involving cADPR which 
control the increase in [Ca+2]int (Wu et al., 1997). In plants, ABA depolarizes plasma 
membranes, which activates potassium ion channels and thereby extrudes K+ outside 
the cells (Schroeder et al., 1987). Ion channel depolarization is dependent on calcium, 
which is an ABA second messenger (Schroeder et al., 2001). The increase in calcium 
concentrations also leads to increased nitric oxide (NO) production (Bodrato et al., 
2009). As calcium signalling is a key regulator of apoptosis, changes in calcium 
distribution in the cell activate cellular cascades which lead to cell death (Hajnoczky 
et al., 2003). Coincidently, some of the pathways activated by ABA and those 
modulated by chemotherapeutic agents used for treating cancer are noticeably similar. 
For instance, several chemotherapeutic agents modulate pathways leading to 
increased intracellular calcium concentrations. Medications such as staurosporine, 
doxorubicin, tamoxifen, and etoposide act as anti-cancer agents which lead to the 
death of cancer cells by increasing [Ca+2]int resulting in oxidative stress followed by 
apoptosis (Kruman et al., 1998; Panaretakis et al., 2005; Parihar et al., 2008). Unlike 
some chemotherapeutic agents which act as cell killers, ABA may regulate cancerous 
cells by stimulating the immune system or inducing cancer cells to undergo apoptosis 
without significant toxic effects on normal cells. Further in-vivo studies are warranted 
for finding efficacy and molecular mechanisms for anti-cancer effect. 
In plants, it has been demonstrated that ABA stimulates release of intracellular 
calcium in conjunction with the upregulation of cADPR (Wu et al, 1997). ABA 
functions through a markedly similar signalling pathway in both plants and animals, 
which is thought to involve cADPR and Ca+2 functioning as intermediates. As 
calcium is an important regulator of cell function, we tried to check effect of abscisic 
in smooth muscle and CVS parameters. 
In our study we found that abscisic acid neither produced any contractile response nor 
reduced contractile response of BaCl2 on isolated rat ileum preparation. Current 
findings suggest that ABA is not producing any significant effect on smooth muscle 
preparation. Our finding supports previous report claiming that ABA is devoid of any 
substantial Ca+2 channel modulatory activity in rat smooth muscle preparations 
(Masters et al., 1994). Administration of ABA in in-vivo anaesthetized rat showed 
insignificant increase in heart rate and blood pressure.  
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In our study, abscisic acid did not show any observable toxicity in our study, 
suggesting a safe profile for its potential therapeutic use. 
Thus, the findings of our study suggest that administration of abscisic acid may be 
beneficial for protecting functional efficiency of pancreatic β cells, probably by 
facilitating action of insulin and potent anti-cancer activity due to its putative 
immune-stimulant activity or through its ability to modulate calcium signalling 
process leading to apoptosis. 
 
 
 
 
 
  
 
  
 
 
Conclusions 
 Conclusion 
[102] Devang B. Sheth 
 
Results of our project suggest that administration of abscisic acid may be beneficial 
for protecting functional efficiency of pancreatic β cells, probably by facilitating 
action of insulin and thereby preventing emergence of insulin resistance. The putative 
action of ABA on PPAR-γ receptors is most probable mechanism for its therapeutic 
effect in insulin resistance. Further studies are warranted to establish safety and 
efficacy of abscisic acid in management of diabetes mellitus. 
In the present project, abscisic acid exhibited potent anti-cancer activity in in-vitro 
cell line study. We observed that abscisic acid exerts cytotoxic action in both ER 
positive (MCF-7) as well as ER negative (MDA-MB 468) breast cancer cell line 
studies indicating that its action is not mediated through RAR and/or RXR signalling 
mechanisms. Thus, anti-cancer activity of abscisic acid is not related to estrogen 
receptor expression. Cytotoxic effects of ABA may be due to its immune-stimulant 
activity or its ability to modulate calcium signalling process that may lead to 
apoptosis.  
Abscisic acid did not show any observable toxicity in our study, suggesting a safe 
profile for its potential therapeutic utility. 
We conclude that pharmacologically, abscisic acid is a therapeutically promising 
phytohormone with beneficial effects in ailments like diabetes mellitus and cancer 
along with a high safety profile. 
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ABSTRACT: 
Insulin resistance is a metabolic disorder that prevails worldwide and plays a role in 
pathophysiology of most common human diseases including type 2 diabetes mellitus, hypertension, obesity, 
dyslipidemia and coronary heart disease. Insulin resistance can be induced by fructose-rich diet in rats. One 
of most effective medications in treatment of insulin resistance has been thiazolidinediones (TZDs). TZDs 
are reported to have some troublesome adverse effects. Abscisic acid is a phytohormone with structural 
similarity to TZDs. We investigated effects of 2-cis, 4-trans abscisic acid on glucose, lipid profile, and 
serum insulin levels in wistar rats fed with high fructose. The animals were divided into 4 groups: normal 
control, disease control (10% fructose in drinking water, 30 days), standard treated (Pioglitazone 10mg/kg 
p.o. with 10% fructose in drinking water, 30 days) and Abscisic acid (ABA) treated (1mg/kg p.o. with 10% 
fructose in drinking water, 30 days) group (n=6). Fructose significantly increased serum fasting glucose 
(p<0.01), serum insulin (p<0.05), FIRI (p<0.01), liver and muscle glycogen (p<0.01) as compared to control 
group. Standard as well as ABA treated group significantly reduced serum glucose (p<0.01), serum insulin 
(p<0.05), FIRI (p<0.01), liver and muscle glycogen (p<0.01) as compared to disease control group. Our 
results show that administration of abscisic acid may be advantageous for preservation of the functional 
efficiency of pancreatic β cells, probably by improving insulin action via PPAR γ agonistic action and 
thereby preventing induction of insulin resistance. 
Keywords: Abscisic acid, Thiazolidinediones, Insulin resistance. 
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1.INTRODUCTION 
Type II diabetes is an insulin resistance disease
1,2
. TZDs are a class of the most effective insulin-sensitizing 
drugs that increase the sensitivity of peripheral tissues to endogenous insulin. TZDs serve as synthetic ligands, and 
activate the key metabolic regulators as well as the transcription factor PPAR-γ3. Therefore, PPAR-γ agonists are 
considered to be a promising target for future drug design and treatment of diseases related to insulin resistance and the 
related conditions of hyperlipidemia, hyperglycemia, and hyperinsulinemia. 
Since its discovery in the early 1960’s, abscisic acid (ABA) has received considerable attention as an important 
phytohormone, and more recently, as a candidate medicinal in humans. Abscisic acid has been reported to be a partial 
peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist4,5. PPAR-γ responsive genes were found to be 
induced or activated by abscisic acid in 3T3-L1 preadipocytes in vitro
3,4
. ABA could also be used as a nutritional 
intervention against type II diabetes and obesity-related inflammation
4
. More over current TZDs are associated with 
weight gain and, in the past, hepatotoxicity
6
. Recently, a study in the New England Journal of Medicine showed that 
use of rosiglitazone was associated with a 43% increase in myocardial infarction and 64% increase in risk of 
cardiovascular mortality
7
. Thus there is surge for need of novel insulin sensitizer without considerable adverse effects. 
Therefore, we studied effect of abscisic acid on in a fructose-induced insulin resistance in rat. 
2. MATERIAL AND METHODS 
2 – cis, 4 – trans abscisic acid (98%, synthetic) was purchased from Sigma Aldrich, USA. All experiments and 
protocols described in present study were approved by the Institutional Animal Ethics Committee (IAEC) of R. K. 
College of Pharmacy, Rajkot and with permission from CPCSEA, Ministry of Social Justice and Empowerment, 
Government of India. 
Ten week old male Sprague-Dawley rats (200 ± 25 gm) were housed in-group of 3 animal in cages and 
maintained under standardized condition (12-h light/dark cycle, 24°C, 35 to 60% humidity) and provided free access to 
palleted diet and purified drinking water ad libitium, unless specified. Rats (n=24) were randomized into 4 groups as 
shown in table 1. 
 
Table 1: Group specification and dose for individual treatment 
 
Group No. Group Specification Treatment (n=6, 30 days) 
I Normal control (CON) Vehicle (water) 
II Disease control (FRU) 10% fructose in water ad libitium 
III Standard (PIO + FRU) 
Pioglitazone (10 mg/kg/day, p.o.) + 10% fructose in 
water ad libitium 
IV Test (ABA + FRU) 
Abscisic acid (1 mg/kg/day, p.o.) + 10% fructose in 
water ad libitium 
 
Rats were weighed and their food/water intake was recorded weekly. On 30
th
 day animals were used for serum 
collection followed by tissue collection. 
 
2.1 Serum fasting glucose, serum fasting insulin and FIRI: 
Serum glucose was measured by using enzymatic kit (ACCUCARE™, Lab – Care Diagnostics India Pvt. 
Ltd.). Serum fasting insulin was estimated at Saurashtra Pathology Laboratory – Rajkot using radio immune assay 
(RIA) kit. Fasting insulin resistance index (FIRI) was calculated by following formula
8
:  
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FIRI = fasting blood glucose in mg/dl x fasting insulin in uU/ml) / 25 
 
2.2 Liver and Muscle Glycogen
9
: 
The liver and thigh muscle were removed and blotted on filter paper to remove blood, weighed, dropped into 
flasks containing 10 ml hot 30% potassium hydroxide and digested on a hot plate. The digest was diluted to 100 ml and 
a 50-fold dilution of an aliquot was used for analysis. Ten ml 0.2% anthrone in 95% sulfuric acid was slowly added to 
5 ml of liver digest dilution with cooling. The mixture was heated in a boiling water bath for 10 min and then placed 
into cold water. Optical density was measured in a spectrophotometer at 620 μm using the anthrone-reagent as blank. 
Calibration curves were established using glucose as standard. 
 
2.3 Statistical Analysis: 
Statistical significance between more than two groups was tested using one-way ANOVA followed by the 
Bonferroni multiple comparisons test or unpaired two-tailed student's t-test as appropriate using computer based fitting 
program (Prism, Graphpad). Differences were considered to be statistically significant when p < 0.05. 
3. RESULTS 
Serum parameters were found to be increasing significantly with administration of 10% fructose feeding for 30 
days. Fructose significantly increased serum fasting glucose (p<0.01), serum insulin (p<0.05) and FIRI (p<0.01) as 
compared to control group (n=6). Pioglitazone (10mg/kg, p.o.) and abscisic acid (1mg/kg, p.o.) both exhibited 
significantly reduction in serum fasting glucose as compared to disease control. Abscisic acid showed significant anti-
hyperglycaemic activity by bringing back serum fasting glucose near to normal as identical to pioglitazone treatment. 
Both abscisic acid and pioglitazone treatment resulted in significant decrease (p<0.05) in fasting insulin 
respectively as compared to in disease control (Table-2, Fig-2). Fasting insulin resistance index (p<0.01) was also 
found to be reduced as compared to fructose treated group (Table-2, Fig-3) indicating improvement in insulin 
resistance produced by fructose feeding.  
 
Table 2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting glucose, serum fasting insulin and FIRI 
in fructose induced insulin resistance in rats 
 
All values represents Mean ± SEM; n=6 
*     Significantly different from normal control (p < 0.05) 
#     Significantly different from disease control (p < 0.05) 
**   Significantly different from normal control (p < 0.01) 
##   Significantly different from disease control (p < 0.01) 
 
 
Treatment 
(n=6) 
Serum fasting glucose 
(mg/dl) 
Serum fasting insulin 
(µU/ml) 
Fasting insulin resistance 
index (FIRI) 
Normal control (CON) 77 ± 1.23 22 ± 0.38 67.76 
Disease control (FRU) 115 ± 4.55 
**
 29 ± 0.15 
*
 133.4 
**
 
Standard (PIO + FRU) 80 ± 0.54 
##
 23 ± 0.42 
#
 73.6 
##
 
Test (ABA + FRU) 82 ± 0.98 
##
 24 ± 0.26 
#
 78.72 
##
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Figure 1: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting glucose in fructose induced insulin 
resistance in rats 
 
 
 
Figure 2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum fasting insulin in fructose induced insulin 
resistance in rats 
 
 
 
Figure-3: Effect of Abscisic acid (1 mg/kg/day, 30 days) on fasting insulin resistance index in fructose induced 
insulin resistance in rats 
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Liver and muscle glycogen stores were found to be decreasing (p<0.01 and p<0.05 respectively) with fructose 
supplement, as compared to control group, indicating development of insulin resistance. Both abscisic acid (1mg/kg) 
and pioglitazone (10mg/kg) treatment increased liver and muscle glycogen stores significantly (p<0.01 and p<0.05 
respectively), as compared to disease control, showing considerable increase in insulin sensitivity (Table-3, Fig-4 and 
5). 
 
Table 3: Effect of Abscisic acid on liver and muscle glycogen in fructose induced insulin resistance in rats 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Effect of Abscisic acid on liver glycogen in fructose induced insulin resistance in rats 
 
 
 
Figure 5: Effect of Abscisic acid (1 mg/kg/day, 30 days) on muscle glycogen in fructose induced insulin 
resistance in rats 
 
 
 
Treatment 
(n=6) 
Liver glycogen 
(µg/mg of tissue) 
Muscle glycogen (µg/mg of 
tissue) 
Normal control (CON) 24.3 ± 2.3 6.2 ± 0.35 
Disease control (FRU) 17.1 ± 1.74 
**
 5.15 ± 0.78 
*
 
Standard (PIO + FRU) 22.35 ± 0.65 
##
 5.95 ± 0.4 
#
 
Test (ABA + FRU) 22 ± 1.95 
##
 6.12 ± 0.89 
#
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4. DISCUSSION 
In the recent decades the prevalence of insulin resistance and type II diabetes has seen a precipitous growth
10
.  
Abscisic acid can ameliorate the symptoms of type II diabetes, targeting PPAR-γ in a similar manner as the 
thiazolidinediones class of anti-diabetic drugs. 
Earlier fructose was considered as one of the glucose alternative in diabetic patients. But afterwards it was 
found that upon chronic usage fructose causes metabolic syndrome including insulin resistance. The long-term negative 
effects can include changes in digestion, absorption, plasma hormone levels, appetite, and hepatic metabolism, leading 
to development of insulin resistance, diabetes, obesity, and inevitably cardiovascular disease
11
. Same results were 
obtained in our study indicated by hyperglycaemia, hyperinsulinaemia and decreased glycogen content in peripheral 
tissues. 
Abscisic acid was found to be decreasing the insulin resistance induced by the fructose feeding. Abscisic acid 
not only decreased the rise in serum fasting glucose and insulin (observed with fructose feeding) but also increased the 
level of liver and muscle glycogen content. Thus, abscisic acid decreases blood sugar level, reduces over-burden on 
pancreatic β cells (by decreasing supernormal serum insulin) and increases uptake of glucose in peripheral tissues like 
liver and muscle. This clearly is indicative of insulin sensitizing action probably via PPAR-γ receptor action. Our result 
confirms previous report showing activation of PPAR-γ responsive genes by abscisic acid in 3T3-L1 preadipocytes in 
vitro
4
. 
Our results show that administration of abscisic acid may be advantageous for preservation of the functional 
efficiency of pancreatic β cells, probably by improving insulin action and thereby preventing induction of insulin 
resistance. Further studies are needed to establish safety and efficacy of abscisic acid in management of diabetes 
mellitus. 
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ABSTRACT
Insulin resistance is a metabolic disorder that prevails worldwide and 
plays a role in pathophysiology of most common human diseases 
including type 2 diabetes mellitus, hypertension, obesity, dyslipidemia 
and coronary heart disease. One of most effective medications in 
treatment of insulin resistance has been thiazolidinediones (TZDs) which 
act by acting through activation of PPAR-γ. TZDs have been shown to be 
very effective in improving insulin sensitivity as well as lipid 
dyslipidaemia through induction of genes such as aP2 and CD36, which 
are important in fatty acid transport, adipogenesis and lipid uptake. 
Abscisic acid (ABA), a phytohormone, is recently shown to possess 
insulin sensitizer activity through PPAR-γ activation. As most of the 
PPAR-γ agonists have the added benefits of being anti-atherogenic, we 
also tried to prove action of ABA in dyslipidaemia induced by high 
fructose feeding. We investigated effects of 2-cis, 4-trans abscisic acid on 
glucose (OGTT) and lipid profile. The animals were divided into 4 
groups: normal control, disease control (10% fructose in drinking water, 
30 days), standard treated (Pioglitazone 10mg/kg p.o.) and abscisic acid 
treated (1mg/kg p.o.) (both along with 10% fructose in drinking water, 30 
days, n=6). Fructose significantly impaired glucose tolerance (p<0.01)
and increased levels of serum total cholesterol, TG, VLDL (p<0.01) while 
decreased serum HDL (p<0.01) as compared to control group. Standard as 
well as ABA treated group significantly improved glucose tolerance 
(p<0.01), increased HDL (p<0.01) and decreased serum LDL, VLDL, and 
TG as compared to disease control group. Our results show that 
administration of ABA not only improve glucose tolerance but also aids 
in improving lipid profile leading to beneficial effects in insulin resistance 
or metabolic syndrome.
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INTRODUCTION
Generally, type 2 diabetes mellitius (T2DM) patients suffer from both hyperglycemia and 
dyslipidemia. The insulin resistant state is commonly associated with lipoprotein abnormalities 
that are risk factors for atherosclerosis, including hypertriglyceridemia, high levels of very low 
density lipoprotein (VLDL), low levels of highdensity lipoprotein cholesterol1, and small, dense 
LDL2. Clinical studies implicate hyperglycemia in the onset of microangiopathic complications 
of T2DM, including kidney failure, retinopathy and peripheral neuropathy. However, the major 
cause of mortality in T2DM patients is atherosclerotic macrovascular disease, which culminates 
in myocardial infarction. Such cardiovascular disease appears to result, in large part, from 
diabetic dyslipidemia3.
TZDs are a class of the most effective insulin-sensitizing drugs that increase the sensitivity of 
peripheral tissues to endogenous insulin by activation of PPAR-γ4,5. Activation of PPAR-γ 
receptor not only treats hyperglycaemia, but also leads to decrease in atherogenic potential.  
They are considered to be a promising target for future drug design and treatment of diseases 
related to insulin resistance and the related conditions of hyperlipidemia, hyperglycemia, and 
hyperinsulinemia.
Since its discovery in the early 1960’s, abscisic acid (ABA) has received considerable attention 
as an important phytohormone, and more recently, as a candidate medicinal in humans. Abscisic 
acid has been reported to be a partial peroxisome proliferator-activated receptor gamma (PPAR-
γ) agonist5,6,7. Abscisic acid is previously reported to ameliorate glucose tolerance in insulin 
resistant rat6. Improvement in lipid profile can be beneficial in insulin resistance and/or 
metabolic syndrome. Therefore, we studied effect of abscisic acid on dyslipidaemia in fructose-
induced insulin resistance in rat.
MATERIAL AND METHODS
2 – cis, 4 – trans abscisic acid (98%, synthetic) was purchased from Sigma Aldrich, USA. All 
experiments and protocols described in present study were approved by the Institutional Animal 
Ethics Committee (IAEC) of R. K. College of Pharmacy, Rajkot and with permission from 
CPCSEA, Ministry of Social Justice and Empowerment, Government of India.
Ten week old male Sprague-Dawley rats (200 ± 25 gm) were housed in-group of 3 animal in 
cages and maintained under standardized condition (12-h light/dark cycle, 24°C, 35 to 60% 
humidity) and provided free access to palleted diet and purified drinking water ad libitium, 
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unless specified. Rats (n=24) were randomized into 4 groups as shown in table 1. Rats were 
weighed and their food/water intake was recorded weekly. On 30th day animals were used for 
serum collection.
Group 
No. Group Specification Treatment (n=6, 30 days)
I Normal control (CON) Vehicle (water)
II Disease control (FRU) 10% fructose in water ad libitium
III Standard (PIO + FRU) Pioglitazone (10 mg/kg/day, p.o.) + 10% fructose 
in water ad libitium
IV Test (ABA + FRU) Abscisic acid (1 mg/kg/day, p.o.) + 10% fructose 
in water ad libitium
Table 1: Group specification and dose for individual treatment
Oral glucose tolerance test (OGTT)8
The oral glucose tolerance test was performed in overnight fasted rats. Rats divided into four 
groups (n=6) were administered drinking water (normal control and disease control), 
pioglitazone and abscisic acid respectively. Glucose (2g/kg) was fed 30 min after the 
administration of drug. Blood was withdrawn from the retro orbital plexus under light ether 
anesthesia at 30, 60,120 min of glucose administration. Serum glucose was measured by using 
enzymatic kit (ACCUCARE™, Lab – Care Diagnostics India Pvt. Ltd.).
Serum lipid profile
In vitro quantitative determination of the activity of total cholesterol and HDL-cholesterol in 
serum was done using enzymatic kit (Monozyme India Limited - CHOD/POD-Phosphotungstate 
method). In vitro quantitative measurement of triglyceride (neutral fat) concentration in serum 
was done by using kit (Reckon India diagnostics Pvt. Ltd. - GPO Method). Estimation of LDL-
cholesterol was done using the Friedewald formula9.
LDL cholesterol = total cholesterol – (HDL cholesterol + VLDL cholesterol)
Estimation of VLDL-cholesterol was done using the Friedewald formula9
VLDL cholesterol = triglycerides / 5
Statistical analysis
Statistical significance between more than two groups was tested using one-way ANOVA 
followed by the Bonferroni multiple comparisons test or unpaired two-tailed student's t-test as 
appropriate using computer based fitting program (Prism, Graphpad). Differences were 
considered to be statistically significant when p < 0.05.
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RESULTS
Serum parameters were found to be increasing significantly with administration of 10% fructose 
feeding for 30 days. Oral glucose tolerance test (OGTT) showed that at all time intervals fructose 
treatment significantly (p<0.01) increased the serum glucose levels as compared to normal 
group. Abscisic acid as well as pioglitazone treatment significantly (p<0.01) decreased the 
fasting serum glucose levels as compared to fructose treated animals (Table
acid showed significant improvement in glucose tolerance produced by fructose feeding.
Table-2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on oral glucose tolerance test (OGTT) in 
fructose induced insulin resistance in rats
Figure-1: Effect of Abscisic acid (1 mg/kg/day, 30 days) on oral glucose tolerance test in 
fructose induced insulin resistance in rats 
Fructose feeding significantly decreased serum HDL (p<0.01) and increased serum total 
cholesterol (p<0.01), serum triglycerides 
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(n=6)
Normal control (CON)
Disease control (FRU)
Standard (PIO + FRU)
Test (ABA + FRU)
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(p<0.01) as compared to control.  Both abscisic acid and pioglitazone treatment resulted in 
significant increase (p<0.05) in serum HDL as compared to disease control. Abscisic acid and 
pioglitazone treatment both decreased the rise in total serum cholesterol (p<0.01), serum 
triglycerides (p<0.01), serum LDL (p<0.01) and serum VLDL (p<0.05) observed with fructose 
feeding significantly. Although abscisic acid (1mg/kg) and pioglitazone (10mg/kg) treatment 
both decreased lipid abnormalities significantly effect of abscisic acid was apparently more on 
serum TG as compared to pioglitazone treatment (Table
Table-3: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum lipid profile parameters in 
fructose induced insulin resistance in rats
All values represents Mean ± SEM; n=6
*Significantly different from normal control (p < 0.05)
control (p < 0.05), **   Significantly different from normal control (p < 0.01)
different from disease control (p < 0.01)
Figure-2: Effect of Abscisic acid (1 mg/kg/day, 30 days) on serum total cholesterol, 
triglycerides, HDL, LDL and VLDL in fructose induced insulin resistance in rats
Lipid profile parameters 
(mg/dl) Normal control 
Serum Total Cholesterol
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Serum LDL
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DISCUSSION
Insulin resistance is a metabolic disorder that prevails worldwide and plays a role in 
pathophysiology of most common human diseases including type 2 diabetes mellitus, 
hypertension, obesity, dyslipidemia and coronary heart disease. Research has proved that 
mortality due to cardiovascular disease associated with diabetic dyslipidaemia is increased3.
Chronic fructose feeding is associated with insulin resistance and metabolic abnormalities. ABA 
was shown to decrease serum fasting glucose and glucose intolerance significantly. This is in 
compliance with previously reported study showing use of dietary abscisic acid in ameliorating 
glucose tolerance in db/db mice fed high-fat diets6. Our study confirms anti-hyperglycaemic 
activity of ABA in insulin resistance. It also been reported that fructose causes the metabolic 
syndrome through involvement of leptin, adiponectin, and free fatty acids10,11. Same results were 
obtained in our study indicated by hyperglycaemia and dyslipidaemia in disease control group. 
Many of the genes induced by PPAR-γ, such as aP2 and CD36, are important in fatty acid 
transport, adipogenesis and lipid uptake. Studies have shown that PPAR-γ is an essential 
participant in the differentiation of pre-adipocytes into adipocytes, particularly in the 
subcutaneous adipose tissue depots. This function has been proposed to enhance systemic insulin
sensitivity by inhibiting lipid efflux from adipose tissue into tissues such as the liver, pancreas, 
skeletal muscle, which are important for the proper regulation of glucose homeostasis12,13. 
PPAR-γ agonists, such as thiazolidinediones (TZDs), have been shown to be very effective in 
improving insulin sensitivity as well as lipid dyslipidaemia14. Present study confirms effect of 
pioglitazone on reducing dyslipidaemia through PPAR-γ activation. Similar pattern of results 
have been observed with ABA treatment in our study. Although both pioglitazone and ABA 
decreased TG, LDL, and total cholesterol significantly; effect of ABA was remarkably better on 
levels of TG as compared to pioglitazone. Increased delivery of triglycerides or non-esterified 
fatty acids to the muscle interferes with the utilization of glucose, through the principles of 
Randle cycle15, impairing the insulin action. Thus, reduction in dyslipidaemia especially 
hypertriglyceridaemia may be correlated with improved insulin sensitivity.
Our results show that administration of ABA not only improve glucose tolerance but also aids in 
improving lipid profile leading to beneficial effects in insulin resistance or metabolic syndrome. 
Further studies are needed to establish safety and efficacy of abscisic acid in management of 
insulin resistance and associated metabolic complications.
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